cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"In a White male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden of 18.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment indicates a tumor mutational burden of 18.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Assess the tumor microenvironment’s transcriptomic profile with the COMPASS tool to forecast treatment response. Specifically, analyze immune deficiency markers—including NK cells, exhausted T cells, general B cells, and plasma cells—alongside the COMPASS prediction. Use these findings, reinforced by key transcriptomic indicators of immune activity, to determine the likelihood of a patient responding to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 1.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 1.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment for predicting treatment response. Focus on evaluating immune deficiency markers, including natural killer cells, exhausted T cells, B cells, and plasma cells, and integrate these findings with the COMPASS prediction and other key transcriptomic markers of immune activity to estimate the likelihood of a favorable treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 44.0. Based on these parameters, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 44.0. Based on these parameters, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Apply the COMPASS tool to analyze the tumor microenvironment’s transcriptomic profile with a focus on immune deficiency markers, specifically natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these findings with the overall COMPASS prediction and other relevant transcriptomic indicators of immune function to assess the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For a white female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was characterized by transcriptomic analysis from a lymph node biopsy and who has a tumor mutational burden of 2.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was characterized by transcriptomic analysis from a lymph node biopsy and who has a tumor mutational burden of 2.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Use the COMPASS tool to examine the tumor microenvironment’s transcriptomic profile, focusing on indicators of immune deficiency such as natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS prediction and other key transcriptomic markers of immune function to evaluate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0 mutations per megabase. Given these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 8.0 mutations per megabase. Given these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS tool to analyze the tumor microenvironment’s transcriptome, specifically evaluating markers of immune deficiency such as natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these findings with the overall COMPASS prediction and other significant transcriptomic indicators of immune function to assess the potential for a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"For my WHITE F patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my WHITE F patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS tool to evaluate the tumor microenvironment's transcriptome by quantifying markers associated with immune deficiency—specifically, natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS score and other relevant transcriptomic indicators of immune function to determine the likelihood of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0, as determined from transcriptomic analysis of the tumor immune microenvironment obtained via kidney biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0, as determined from transcriptomic analysis of the tumor immune microenvironment obtained via kidney biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to analyze the transcriptome of the tumor microenvironment, specifically measuring markers related to immune deficiency. Focus on quantifying markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these findings with the overall COMPASS score and other relevant transcriptomic indicators of immune function to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"In a White male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 18.0. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a TMB of 18.0. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy? Use the COMPASS tool to perform a detailed transcriptomic analysis of the tumor microenvironment, concentrating on immune deficiency markers. Specifically, quantify the markers associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS score and other relevant transcriptomic indicators of immune function to evaluate the probability of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutation burden is not available. Based on these factors, what is the probability of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutation burden is not available. Based on these factors, what is the probability of a positive response to Atezolizumab therapy? Use the COMPASS tool to conduct a comprehensive transcriptomic analysis of the tumor microenvironment with an emphasis on identifying immune deficiency markers. Specifically, quantify markers linked to natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining these data, combine them with the overall COMPASS score and additional relevant transcriptomic indicators of immune function to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"Given a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via nano-biopsy and who has a tumor mutational burden of [nan], how likely is it that he will respond favorably to Atezolizumab therapy?","Given a white male patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment was profiled via nano-biopsy and who has a tumor mutational burden of [nan], how likely is it that he will respond favorably to Atezolizumab therapy? Please use the COMPASS tool to perform an in-depth transcriptomic evaluation of the tumor microenvironment. In this analysis, focus on quantifying markers associated with immune deficiencies, particularly those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Once these measurements are obtained, integrate them with the overall COMPASS score and additional transcriptomic indicators of immune function to assess the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 based on transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 based on transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to carry out a comprehensive transcriptomic assessment of the tumor microenvironment. Concentrate on quantifying markers that reflect immune deficiencies, specifically those linked to natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining these values, combine them with the overall COMPASS score and other transcriptomic indicators of immune function to evaluate the potential for a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile obtained from a bladder biopsy and a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile obtained from a bladder biopsy and a tumor mutational burden of 8.0, what is the likelihood of a favorable response to atezolizumab therapy? Perform a detailed transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Focus on measuring markers that indicate immune deficits, particularly those associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have these values, integrate them with the overall COMPASS score and other relevant transcriptomic markers of immune function to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), with transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden (TMB) reported as nan, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), with transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and a tumor mutation burden (TMB) reported as nan, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please perform a comprehensive transcriptomic evaluation of the tumor microenvironment using the COMPASS tool. Specifically, quantify markers that reveal immune system deficits, focusing on those associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these measurements with the overall COMPASS score and additional relevant transcriptomic markers of immune function to determine the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 9.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 9.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Conduct a thorough transcriptomic analysis of the tumor microenvironment using the COMPASS tool. In this evaluation, quantify markers that indicate immune deficiencies, with a particular focus on those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS score and any additional relevant transcriptomic indicators of immune function to assess the likelihood of a beneficial treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 4.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 4.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Perform a comprehensive transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Focus specifically on quantifying markers that reflect immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these data with the overall COMPASS score and any other relevant transcriptomic indicators of immune function to evaluate the potential for a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma and exhibiting a tumor mutation burden of 32.0, how likely is he to respond positively to Atezolizumab, considering the transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy?","In a white male patient diagnosed with bladder urothelial carcinoma and exhibiting a tumor mutation burden of 32.0, how likely is he to respond positively to Atezolizumab, considering the transcriptomic profile of his tumor immune microenvironment obtained from a ureter biopsy? Conduct a detailed transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Specifically, quantify markers indicating immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these marker profiles with the overall COMPASS score and any other relevant transcriptomic indicators of immune function to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 21, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile reveals a tumor mutational burden of 21, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Perform a comprehensive transcriptomic evaluation of the tumor microenvironment using the COMPASS tool. Start by quantifying markers associated with immune deficits in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these marker profiles with the overall COMPASS score and additional relevant transcriptomic indicators of immune function to assess the potential for a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 10.0, based on the transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 10.0, based on the transcriptomic analysis of his tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy? Conduct a thorough transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Begin by quantifying markers that indicate immune deficits in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, integrate these profiles with the overall COMPASS score and additional transcriptomic indicators of immune function to evaluate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 38.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 38.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Perform a comprehensive transcriptomic analysis of the tumor microenvironment using the COMPASS tool. Start by quantifying markers associated with immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these measurements with the overall COMPASS score and other transcriptomic indicators of immune function to assess the probability of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a TMB of 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a TMB of 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Using the COMPASS tool, start by quantifying markers that indicate immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these marker measurements with the overall COMPASS score and other transcriptomic indicators of immune function. This integrated analysis will help determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 5.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 5.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS tool to measure markers that indicate immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these measurements with the overall COMPASS score and additional transcriptomic indicators of immune function. This comprehensive analysis will allow us to estimate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"In our white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutation burden of 15.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","In our white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutation burden of 15.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to quantify markers reflecting immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these values with the overall COMPASS score and additional transcriptomic markers of immune function to help assess the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy and who has a reported tumor mutation burden of nan, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy and who has a reported tumor mutation burden of nan, what is the likelihood of a positive response to Atezolizumab therapy? Please employ the COMPASS tool to quantify markers indicative of immune deficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these measurements with the overall COMPASS score and additional transcriptomic markers of immune function to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a lung biopsy. Given that the tumor mutation burden (TMB) data is unavailable, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a lung biopsy. Given that the tumor mutation burden (TMB) data is unavailable, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to assess markers of immune deficiency in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and additional transcriptomic markers of immune function to determine the probability of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"For my White male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For my White male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Begin by using the COMPASS tool to evaluate markers of immune deficiency in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these findings with the overall COMPASS score and additional transcriptomic markers of immune function to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"For my African American male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my African American male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Step one: Use the COMPASS tool to assess immune deficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Step two: Combine these findings with both the overall COMPASS score and relevant transcriptomic markers of immune function to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 19.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 19.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is a positive response to Atezolizumab therapy? First, use the COMPASS tool to evaluate immune deficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and key transcriptomic markers of immune function to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"For my white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor immune microenvironment with a tumor mutational burden (TMB) of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile indicates a tumor immune microenvironment with a tumor mutational burden (TMB) of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by using the COMPASS tool to assess immune deficiency markers for natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these results with the overall COMPASS score and important transcriptomic markers related to immune function to evaluate the likelihood of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutation burden (TMB) of 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutation burden (TMB) of 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Start by using the COMPASS tool to evaluate immune deficiency indicators in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, integrate these findings with the overall COMPASS score and key transcriptomic markers of immune function to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed, and his tumor mutational burden is 8.0. Based on these findings, what is his likelihood of responding favorably to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed, and his tumor mutational burden is 8.0. Based on these findings, what is his likelihood of responding favorably to atezolizumab therapy? Begin by using the COMPASS tool to assess markers of immune deficiency in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, incorporate these results with the overall COMPASS score and critical transcriptomic markers of immune function to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"For my white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutation burden of 13.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutation burden of 13.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? First, use the COMPASS tool to evaluate immune deficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and key transcriptomic indicators of immune activity to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy to obtain a transcriptomic profile of the tumor immune microenvironment and has a tumor mutational burden of 16.0 mutations/Mb, what is his estimated likelihood of responding positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who underwent a kidney biopsy to obtain a transcriptomic profile of the tumor immune microenvironment and has a tumor mutational burden of 16.0 mutations/Mb, what is his estimated likelihood of responding positively to Atezolizumab therapy? Begin by employing the COMPASS tool to assess immune deficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS score along with key transcriptomic indicators of immune activity to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutation burden of 2.0, how does the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy inform the likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma and a tumor mutation burden of 2.0, how does the transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy inform the likelihood of a positive response to Atezolizumab therapy? First, use the COMPASS tool to evaluate immune deficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these findings with the overall COMPASS score and important transcriptomic markers of immune activity to assess the probability of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Begin by assessing immune deficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Then, integrate these results with the overall COMPASS score and relevant transcriptomic markers of immune activity to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"For my White male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? First, evaluate immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells with the COMPASS tool. Then, integrate these findings with the overall COMPASS score and the pertinent transcriptomic markers of immune activity to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled from a biopsy and who exhibits a tumor mutational burden of 20.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma whose tumor immune microenvironment has been profiled from a biopsy and who exhibits a tumor mutational burden of 20.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by using the COMPASS tool to assess immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these results with the overall COMPASS score and relevant transcriptomic indicators of immune activity to estimate the likelihood of a positive treatment outcome.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a Caucasian female patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment has been performed and the tumor mutational burden is 5.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment has been performed and the tumor mutational burden is 5.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy? First, utilize the COMPASS tool to evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and pertinent transcriptomic markers of immune activation to assess the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"For my Caucasian male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from his bladder biopsy indicates a tumor mutation burden of 38.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, the tumor transcriptomic profile from his bladder biopsy indicates a tumor mutation burden of 38.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Begin by using the COMPASS tool to measure immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these data with the overall COMPASS score and relevant transcriptomic indicators of immune activation to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? First, use the COMPASS tool to quantify immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these results with the overall COMPASS score and relevant transcriptomic indicators of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile of the immune microenvironment shows a TMB of 8.0. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor biopsy transcriptomic profile of the immune microenvironment shows a TMB of 8.0. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy? Begin by using the COMPASS tool to evaluate immunodeficiency markers across natural killer cells, exhausted T cells, B cells, and plasma cells. Next, combine these findings with the overall COMPASS score and pertinent transcriptomic markers of immune activation to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a bladder biopsy. With a tumor mutation burden of 13.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a bladder biopsy. With a tumor mutation burden of 13.0, what is the likelihood that he will respond favorably to Atezolizumab therapy? Use the COMPASS tool to assess immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and key transcriptomic markers of immune activation to evaluate how likely the patient is to respond positively to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these parameters, what is the likelihood of a positive therapeutic response to Atezolizumab?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these parameters, what is the likelihood of a positive therapeutic response to Atezolizumab? Apply the COMPASS tool to evaluate immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Next, integrate these results with both the overall COMPASS score and significant transcriptomic indicators of immune activation to determine the patient’s likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 5.0, how likely is she to respond favorably to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutation burden of 5.0, how likely is she to respond favorably to atezolizumab therapy? Use the COMPASS tool to assess immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these findings with the overall COMPASS score and key transcriptomic indicators of immune activation to evaluate the patient's likelihood of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden (TMB) is 5.0. Based on these results, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden (TMB) is 5.0. Based on these results, what is the predicted likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS tool to evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Next, integrate these results with the overall COMPASS score and key transcriptomic indicators of immune activation to determine the patient’s potential for a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from an additional biopsy was performed. The patient’s tumor mutational burden is reported as ""nan."" Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from an additional biopsy was performed. The patient’s tumor mutational burden is reported as ""nan."" Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy? Use the COMPASS tool to assess immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these findings with the overall COMPASS score and essential transcriptomic markers of immune activation to evaluate the patient’s likelihood of responding positively to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"For my white female patient with bladder urothelial carcinoma, based on the transcriptomic profile from her lymph node biopsy and a tumor mutational burden of 12.0 mutations per megabase, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, based on the transcriptomic profile from her lymph node biopsy and a tumor mutational burden of 12.0 mutations per megabase, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to evaluate immunodeficiency markers specifically in natural killer cells, exhausted T cells, B cells, and plasma cells. After collecting these data, integrate the results with the overall COMPASS score and key transcriptomic markers of immune activation to assess the patient’s probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 1.0, and where transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been completed, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden (TMB) of 1.0, and where transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been completed, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS tool to assess immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these measurements are obtained, combine them with the overall COMPASS score and the primary transcriptomic indicators of immune activation to determine the patient's likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile indicates a tumor mutation burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile indicates a tumor mutation burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to evaluate immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells. After collecting these measurements, integrate them with the overall COMPASS score and key transcriptomic markers of immune activation to estimate the likelihood that the patient will respond favorably to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"For a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a female patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please assess the immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Then, integrate these findings with the overall COMPASS score and key transcriptomic markers of immune activation to determine the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"Given the transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 6.0 in my White male patient with bladder urothelial carcinoma, what is the estimated likelihood that he will respond favorably to atezolizumab therapy?","Given the transcriptomic profile of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 6.0 in my White male patient with bladder urothelial carcinoma, what is the estimated likelihood that he will respond favorably to atezolizumab therapy? Evaluate immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Then, combine these results with the overall COMPASS score and important transcriptomic indicators of immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 22. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor’s immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 22. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Assess immunodeficiency markers in natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Then, integrate these findings with the overall COMPASS score and key transcriptomic indicators of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 1.0, how likely is he to respond positively to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 1.0, how likely is he to respond positively to Atezolizumab therapy? Evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Then, combine these findings with the comprehensive COMPASS score and key transcriptomic indicators of immune activation to assess the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment, and with the tumor mutational burden (TMB) reported as not available, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment, and with the tumor mutational burden (TMB) reported as not available, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS tool to analyze immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the overall COMPASS score and key transcriptomic indicators of immune activation to determine the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"I am managing a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these data, what is the likelihood that he will respond favorably to Atezolizumab therapy?","I am managing a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0. We obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. Based on these data, what is the likelihood that he will respond favorably to Atezolizumab therapy? Apply the COMPASS tool to assess immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine these results with the overall COMPASS score and key transcriptomic markers of immune activation to evaluate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a TMB of 11.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a TMB of 11.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Use the COMPASS tool to evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with both the overall COMPASS score and key transcriptomic markers of immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"For a white male patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy and a tumor mutational burden of 9.0, what is the anticipated likelihood of a positive response to Atezolizumab?","For a white male patient with bladder urothelial carcinoma, based on transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy and a tumor mutational burden of 9.0, what is the anticipated likelihood of a positive response to Atezolizumab? Please use the COMPASS tool to assess immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been evaluated, combine the results with the overall COMPASS score and key transcriptomic indicators of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy, and the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy, and the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. After assessing these markers, integrate the overall COMPASS score with key transcriptomic indicators of immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Use the COMPASS tool to assess immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers are evaluated, combine the resulting COMPASS score with key transcriptomic indicators of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"For our white male patient diagnosed with bladder urothelial carcinoma and exhibiting a tumor mutational burden of 18.0, with transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For our white male patient diagnosed with bladder urothelial carcinoma and exhibiting a tumor mutational burden of 18.0, with transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to evaluate immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the COMPASS score, integrate it with key transcriptomic indicators of immune activation to assess the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For my white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment and demonstrates a TMB of 13.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment and demonstrates a TMB of 13.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS tool to measure immunodeficiency markers on natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have the COMPASS score, combine it with selected transcriptomic indicators of immune activation to evaluate the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For my Black or African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile has been assessed via transcriptomics and shows a tumor mutational burden of 8.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Black or African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile has been assessed via transcriptomics and shows a tumor mutational burden of 8.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to assess immunodeficiency across natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the COMPASS score, integrate this result with selected transcriptomic markers that indicate immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"For my Caucasian female patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0, how likely is she to have a positive therapeutic response to Atezolizumab based on the transcriptomic profiling of her tumor immune microenvironment?","For my Caucasian female patient with bladder urothelial carcinoma who has a tumor mutational burden of 6.0, how likely is she to have a positive therapeutic response to Atezolizumab based on the transcriptomic profiling of her tumor immune microenvironment? Apply the COMPASS tool to evaluate immunodeficiency in natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the COMPASS score, combine it with specific transcriptomic markers of immune activation to gauge the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates an undefined tumor mutation burden (TMB), what is the likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile of the tumor immune microenvironment indicates an undefined tumor mutation burden (TMB), what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to assess immunodeficiencies among natural killer cells, exhausted T cells, B cells, and plasma cells. Once you obtain the COMPASS score, incorporate relevant transcriptomic markers of immune activation to determine the probability of a favorable response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 23.0, based on the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 23.0, based on the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS tool to evaluate immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have obtained the COMPASS score, incorporate the relevant transcriptomic markers of immune activation to estimate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For my White female patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, and her tumor mutation burden is reported as ""nan."" Based on these findings, what is her likelihood of responding positively to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, and her tumor mutation burden is reported as ""nan."" Based on these findings, what is her likelihood of responding positively to Atezolizumab therapy? Please use the COMPASS tool to assess potential immunodeficiencies affecting natural killer cells, exhausted T cells, B cells, and plasma cells. After determining the COMPASS score, integrate the associated transcriptomic markers of immune activation to estimate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden of 2.0. Based on these findings, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden of 2.0. Based on these findings, what is the anticipated likelihood of a positive response to atezolizumab therapy? Use the COMPASS tool to evaluate potential immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Once you calculate the COMPASS score, incorporate the relevant transcriptomic markers of immune activation to gauge the probability of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"For our white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is currently not available. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is currently not available. Based on this information, what is the likelihood that he will respond favorably to Atezolizumab therapy? Utilize the COMPASS tool to assess for potential immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. After calculating the COMPASS score, integrate the identified transcriptomic markers of immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 7.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 7.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Apply the COMPASS tool to evaluate for immunodeficiencies affecting natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have the COMPASS score, incorporate the transcriptomic markers indicative of immune activation to estimate the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For my Asian male patient diagnosed with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a biopsy shows a tumor mutation burden of 1.0. Based on these findings, what are the implications for a positive response to Atezolizumab therapy?","For my Asian male patient diagnosed with bladder urothelial carcinoma, the transcriptomic profile of the tumor immune microenvironment obtained from a biopsy shows a tumor mutation burden of 1.0. Based on these findings, what are the implications for a positive response to Atezolizumab therapy? Please use the COMPASS tool to assess for immunodeficiencies involving natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the COMPASS score, review the transcriptomic markers related to immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and whose tumor immune microenvironment was profiled via a ureter biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 7.0 and whose tumor immune microenvironment was profiled via a ureter biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please employ the COMPASS tool to evaluate potential immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Then, after calculating the COMPASS score, review the immune activation transcriptomic markers to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Use the COMPASS tool to assess for immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. After obtaining the COMPASS score, review the immune activation transcriptomic markers to estimate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 6.0. Based on these parameters, what is the likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 6.0. Based on these parameters, what is the likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS tool to evaluate for immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have determined the COMPASS score, review the immune activation transcriptomic markers to assess the potential for a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a lung biopsy and whose tumor mutational burden is not available, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a lung biopsy and whose tumor mutational burden is not available, what is the expected likelihood of a positive response to Atezolizumab therapy? Please assess for immunodeficiencies in natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. Once you have determined the COMPASS score, review the specific immune activation transcriptomic markers to evaluate the potential for a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile indicates a tumor mutation burden (TMB) of 2.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile indicates a tumor mutation burden (TMB) of 2.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Evaluate the function of natural killer cells, exhausted T cells, B cells, and plasma cells for immunodeficiencies using the COMPASS tool. Once you obtain the COMPASS score, examine the specific immune activation transcriptomic markers to determine the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), we analyzed the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 44.0. Based on these findings, what is the likelihood that he will respond positively to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), we analyzed the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 44.0. Based on these findings, what is the likelihood that he will respond positively to atezolizumab therapy? Assess the functions of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiencies using the COMPASS tool. After obtaining the COMPASS score, review the specific transcriptomic markers of immune activation to gauge the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment was obtained via a kidney biopsy, and his tumor mutational burden is 15 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment was obtained via a kidney biopsy, and his tumor mutational burden is 15 mutations per megabase. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Evaluate the function of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiencies using the COMPASS tool. Once you have obtained the COMPASS score, review the relevant transcriptomic markers of immune activation to determine the likelihood of a positive response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"For my white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment and tumor mutational burden (TMB) of 17.0 have been evaluated, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment and tumor mutational burden (TMB) of 17.0 have been evaluated, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Assess the functionality of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiencies using the COMPASS tool. After calculating the COMPASS score, examine the associated transcriptomic markers of immune activation to determine the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and whose tumor immune microenvironment was profiled via a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and whose tumor immune microenvironment was profiled via a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the function of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiencies using the COMPASS tool. Once you have determined the COMPASS score, examine the related transcriptomic markers of immune activation to estimate the likelihood of a favorable response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"For my white male patient with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, although the tumor mutational burden is not available (NaN). Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, although the tumor mutational burden is not available (NaN). Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please assess the function of natural killer cells, exhausted T cells, B cells, and plasma cells in immunodeficient patients using the COMPASS tool. After calculating the COMPASS score, review the associated transcriptomic markers of immune activation to predict the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as not available. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as not available. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the activity of natural killer cells, exhausted T cells, B cells, and plasma cells in immunodeficient patients using the COMPASS tool. Once you obtain the COMPASS score, examine the related transcriptomic markers of immune activation to estimate the probability of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 12.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 12.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy? Assess the activity of natural killer cells, exhausted T cells, B cells, and plasma cells in immunodeficient patients using the COMPASS tool. Once the COMPASS score is determined, review the associated transcriptomic markers of immune activation to estimate the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 6.0 mutations/Mb, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile from a bladder biopsy reveals a tumor mutational burden of 6.0 mutations/Mb, what is the estimated likelihood of a favorable response to atezolizumab therapy? Evaluate the activity of natural killer cells, exhausted T cells, B cells, and plasma cells in immunodeficient patients using the COMPASS tool. After obtaining the COMPASS score, review the corresponding transcriptomic markers of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, evaluated via transcriptomic analysis of the tumor immune microenvironment from a biopsy and exhibiting a tumor mutational burden of 5.0 mutations/megabase, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, evaluated via transcriptomic analysis of the tumor immune microenvironment from a biopsy and exhibiting a tumor mutational burden of 5.0 mutations/megabase, what is the expected likelihood of a positive response to Atezolizumab therapy? Assess the function of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiency using the COMPASS tool. Once you obtain the COMPASS score, examine the relevant transcriptomic markers of immune activation to assess the probability of a favorable response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment via a nanobiopsy, and his tumor mutational burden is 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment via a nanobiopsy, and his tumor mutational burden is 8.0 mutations/Mb. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the performance of natural killer cells, exhausted T cells, B cells, and plasma cells in patients with immunodeficiency using the COMPASS tool. After calculating the COMPASS score, review the corresponding transcriptomic markers of immune activation to determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment (from a bladder biopsy) revealed a tumor mutational burden (TMB) of 8.0 mutations/Mb. Based on these findings, what is the likelihood that this patient will have a positive response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment (from a bladder biopsy) revealed a tumor mutational burden (TMB) of 8.0 mutations/Mb. Based on these findings, what is the likelihood that this patient will have a positive response to atezolizumab therapy? For patients with immunodeficiency, assess the functional performance of natural killer cells, exhausted T cells, B cells, and plasma cells using the COMPASS tool. After obtaining the COMPASS score, review the related transcriptomic markers of immune activation to estimate the likelihood of a favorable treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"For a patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden (TMB) of 0.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a tumor mutational burden (TMB) of 0.0, what is the estimated likelihood of a positive response to atezolizumab therapy? For patients with immunodeficiency, please use the COMPASS tool to evaluate the functionality of natural killer cells, the extent of T cell exhaustion, as well as the performance of B cells and plasma cells. After obtaining the COMPASS score, review the corresponding transcriptomic markers of immune activation to help estimate the probability of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"For our white male patient with bladder urothelial carcinoma, the transcriptomic profile from the kidney biopsy reveals a tumor mutational burden of 5.0. Given this information, how likely is a favorable response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, the transcriptomic profile from the kidney biopsy reveals a tumor mutational burden of 5.0. Given this information, how likely is a favorable response to Atezolizumab therapy? For immunodeficient patients, please use the COMPASS tool to assess natural killer cell function, quantify T cell exhaustion, and evaluate B cell and plasma cell performance. Once you have obtained the COMPASS score, review the associated transcriptomic markers of immune activation to help determine the likelihood of a positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, a kidney biopsy has provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 6. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, a kidney biopsy has provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 6. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiency, please use the COMPASS tool to evaluate natural killer cell activity, measure T cell exhaustion levels, and assess the performance of both B cells and plasma cells. Once you have determined the COMPASS score, review the corresponding transcriptomic markers of immune activation to help predict the likely positive treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her tumor mutational burden is reported as 'nan.' How might these parameters inform the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and her tumor mutational burden is reported as 'nan.' How might these parameters inform the likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiency, please use the COMPASS tool to assess natural killer cell function, evaluate T cell exhaustion, and measure the performance of both B cells and plasma cells. After obtaining the COMPASS score, review the associated transcriptomic markers of immune activation to help predict which patients are most likely to respond positively to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 59.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 59.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? For immunodeficient patients, please use the COMPASS tool to evaluate the function of natural killer cells, assess T cell exhaustion, and measure the activity of both B cells and plasma cells. After obtaining the COMPASS score, review the corresponding transcriptomic markers of immune activation to help identify which patients are most likely to respond favorably to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For a Caucasian male with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis indicates a tumor mutational burden of 13.0 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma, whose kidney biopsy transcriptomic analysis indicates a tumor mutational burden of 13.0 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, please apply the COMPASS tool to examine natural killer cell function, evaluate T cell exhaustion, and assess the activity of both B cells and plasma cells. After determining the COMPASS score, review the related transcriptomic markers of immune activation to identify those patients most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"For my patient with bladder urothelial carcinoma, who has a tumor microenvironment transcriptomic profile from a ureter biopsy and a tumor mutational burden of 12.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my patient with bladder urothelial carcinoma, who has a tumor microenvironment transcriptomic profile from a ureter biopsy and a tumor mutational burden of 12.0, what is the likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, please use the COMPASS tool to assess natural killer cell function, evaluate T cell exhaustion, and measure the activity of both B cells and plasma cells. Once you have calculated the COMPASS score, review the associated transcriptomic markers of immune activation to determine which patients are most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a lymph node biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, please employ the COMPASS tool to evaluate natural killer cell function, assess T cell exhaustion, and measure the activity of both B cells and plasma cells. After calculating the COMPASS score, review the related transcriptomic markers of immune activation to identify those patients who are most likely to respond to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"For a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 11.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 11.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, please use the COMPASS tool to evaluate the function of natural killer cells, assess T cell exhaustion, and measure the activity levels of B cells and plasma cells. Once the COMPASS score is calculated, review the associated transcriptomic markers of immune activation to pinpoint the patients who are most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"For a White male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and for whom transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and for whom transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been performed, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, apply the COMPASS tool to assess natural killer cell function, evaluate T cell exhaustion, and measure the activity of B cells and plasma cells. After calculating the COMPASS score, review the corresponding immune activation transcriptomic markers to identify patients most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, whose kidney biopsy-based transcriptomic analysis of the tumor immune microenvironment shows an unquantifiable tumor mutational burden, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose kidney biopsy-based transcriptomic analysis of the tumor immune microenvironment shows an unquantifiable tumor mutational burden, what is the likelihood of a favorable response to Atezolizumab therapy? For immunodeficient patients, use the COMPASS tool to evaluate natural killer cell performance, assess T cell exhaustion, and determine the activity levels of B cells and plasma cells. Once you have calculated the COMPASS score, examine the relevant immune activation transcriptomic markers to pinpoint those patients who are most likely to respond favorably to the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis shows a tumor mutational burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis shows a tumor mutational burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, please use the COMPASS tool to assess immune function. This assessment should include measurements of natural killer cell activity, evaluations of T cell exhaustion, and determinations of both B cell and plasma cell activity. After calculating the COMPASS score, review the associated immune activation transcriptomic markers to identify those patients who are most likely to respond favorably to the treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"In a Native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 19.0 based on transcriptomic profiling of the tumor immune microenvironment, what is the anticipated likelihood of a positive response to atezolizumab therapy?","In a Native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 19.0 based on transcriptomic profiling of the tumor immune microenvironment, what is the anticipated likelihood of a positive response to atezolizumab therapy? For patients with immunodeficiencies, please perform an assessment of their immune function using the COMPASS tool. This evaluation should measure natural killer cell activity, assess T cell exhaustion, and determine the activity of both B cells and plasma cells. Once the COMPASS score has been calculated, review the corresponding immune activation transcriptomic markers to identify patients who are most likely to have a favorable response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"For a white patient with bladder urothelial carcinoma who has undergone a bladder biopsy to assess the tumor immune microenvironment, and with a reported TMB of ""nan,"" how likely is it that the patient will respond favorably to Atezolizumab therapy?","For a white patient with bladder urothelial carcinoma who has undergone a bladder biopsy to assess the tumor immune microenvironment, and with a reported TMB of ""nan,"" how likely is it that the patient will respond favorably to Atezolizumab therapy? For patients with immunodeficiencies, please conduct an immune function evaluation using the COMPASS tool. This assessment should include measuring natural killer cell activity, evaluating T cell exhaustion, and assessing the function of both B cells and plasma cells. After calculating the COMPASS score, review the relevant immune activation transcriptomic markers to identify those patients most likely to respond favorably to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is not available (nan). Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is not available (nan). Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, please perform an immune function assessment using the COMPASS tool. This evaluation should include measuring natural killer cell activity, examining T cell exhaustion, and assessing the functionality of both B cells and plasma cells. Once you have calculated the COMPASS score, review the associated immune activation transcriptomic markers to determine which patients are most likely to respond well to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden (TMB) of 33.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden (TMB) of 33.0 and whose tumor immune microenvironment was characterized via transcriptomic profiling from a kidney biopsy, what is the likelihood of achieving a positive response to Atezolizumab therapy? For patients with immunodeficiencies, please conduct an immune function assessment using the COMPASS tool. This evaluation should include an analysis of natural killer cell activity, an investigation of T cell exhaustion, and a functional assessment of both B cells and plasma cells. After calculating the COMPASS score, review the relevant immune activation transcriptomic markers to identify which patients are most likely to respond favorably to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a separate biopsy reveals a tumor mutational burden of 32.0. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a separate biopsy reveals a tumor mutational burden of 32.0. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, please perform an immune function evaluation using the COMPASS tool. This assessment should measure natural killer cell activity, evaluate evidence of T cell exhaustion, and test the functionality of both B cells and plasma cells. Once you have determined the COMPASS score, examine the associated immune activation transcriptomic markers to identify patients who are most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"In a white male patient with bladder urothelial carcinoma (BLCA), the tumor transcriptomic profiling indicates a tumor mutational burden of 2.0. Based on these findings, how likely is it that the patient will exhibit a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), the tumor transcriptomic profiling indicates a tumor mutational burden of 2.0. Based on these findings, how likely is it that the patient will exhibit a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, please evaluate their immune function using the COMPASS tool. Specifically, assess natural killer cell activity, analyze indicators of T cell exhaustion, and determine the functional status of both B cells and plasma cells. After calculating the COMPASS score, review the corresponding immune activation transcriptomic markers to identify which patients may benefit most from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"For a patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? For patients with immunodeficiencies, please assess their immune function using the COMPASS tool. Begin by evaluating natural killer cell activity, examining markers of T cell exhaustion, and assessing the functional status of both B cells and plasma cells. Once you have calculated the COMPASS score, review the related immune activation transcriptomic markers to determine which patients are most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"For a White male patient with bladder urothelial carcinoma who underwent a nan biopsy with transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden (TMB) of nan, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma who underwent a nan biopsy with transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden (TMB) of nan, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, use the COMPASS tool to evaluate their immune function. Start by assessing natural killer cell activity, identifying indicators of T cell exhaustion, and examining the functional status of both B cells and plasma cells. After calculating the COMPASS score, review the associated immune activation transcriptomic markers to determine which patients are most likely to respond favorably to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For my Caucasian patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is 9.0, what is the anticipated response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is 9.0, what is the anticipated response to Atezolizumab therapy? For patients with immunodeficiency, use the COMPASS tool to comprehensively assess immune function. Begin by evaluating natural killer cell activity, screening for markers of T cell exhaustion, and assessing the functional status of both B cells and plasma cells. Once you have calculated the COMPASS score, review the corresponding immune activation transcriptomic markers to help identify the individuals most likely to benefit from treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For an Asian female patient with bladder urothelial carcinoma (BLCA) who has a TMB of 12.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For an Asian female patient with bladder urothelial carcinoma (BLCA) who has a TMB of 12.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiency, start by using the COMPASS tool to perform a thorough immune function evaluation. Begin by measuring natural killer cell activity, screening for T cell exhaustion markers, and assessing the function of B cells and plasma cells. After determining the COMPASS score, review the related immune activation transcriptomic markers to identify those patients who may benefit most from targeted treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted that the tumor mutational burden (TMB) is not available. Based on these findings, how likely is it that the patient will respond positively to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted that the tumor mutational burden (TMB) is not available. Based on these findings, how likely is it that the patient will respond positively to Atezolizumab therapy? For patients with immunodeficiency, initiate their evaluation using the COMPASS tool for a comprehensive appraisal of immune function. Begin by assessing natural killer cell activity, screening for T cell exhaustion markers, and evaluating B cell and plasma cell function. Once you obtain the COMPASS score, review the associated immune activation transcriptomic markers to identify patients who are most likely to benefit from targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 11.0 and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 11.0 and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiency, begin their evaluation using the COMPASS tool to thoroughly assess immune function. Start by measuring natural killer cell activity, screening for markers of T cell exhaustion, and evaluating the function of B cells and plasma cells. Once you have determined the COMPASS score, review the related immune activation transcriptomic markers to help identify those patients who might benefit most from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a liver biopsy revealed a tumor mutational burden of 10. Based on these findings, what is the predicted likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a liver biopsy revealed a tumor mutational burden of 10. Based on these findings, what is the predicted likelihood of a favorable response to Atezolizumab therapy? For patients with immunodeficiencies, initiate their assessment with the COMPASS tool to perform a comprehensive evaluation of immune function. Begin by measuring natural killer cell activity, assessing markers indicative of T cell exhaustion, and examining the function of both B cells and plasma cells. Once you have calculated the COMPASS score, review the corresponding immune activation transcriptomic markers to identify patients who are most likely to benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 12 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how likely is he to have a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 12 and available transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, how likely is he to have a positive response to Atezolizumab therapy? For patients with immunodeficiencies, begin their evaluation using the COMPASS tool. Start by assessing natural killer cell activity, checking for markers of T cell exhaustion, and testing the function of both B cells and plasma cells. After calculating the COMPASS score, review the related immune activation transcriptomic markers to determine which patients may benefit most from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"In a patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) reveals a tumor mutation burden of 13.0, what is the likelihood of a positive response to Atezolizumab therapy?","In a patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile (from a bladder biopsy) reveals a tumor mutation burden of 13.0, what is the likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, start their workup with the COMPASS tool. Begin by evaluating natural killer cell function, checking for indicators of T cell exhaustion, and assessing the performance of B cells and plasma cells. Once you calculate the COMPASS score, examine the corresponding transcriptomic markers of immune activation to identify those patients who are most likely to benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"In a White male patient with bladder urothelial carcinoma who has a tumor immune microenvironment profile obtained from a kidney biopsy and a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma who has a tumor immune microenvironment profile obtained from a kidney biopsy and a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with immunodeficiencies, initiate the diagnostic workup using the COMPASS tool. Begin by assessing natural killer cell function, evaluating for signs of T cell exhaustion, and examining the performance of B cells and plasma cells. After determining the COMPASS score, review the associated transcriptomic markers of immune activation to identify those patients who are most likely to benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 21. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden (TMB) of 21. Based on these findings, what is the estimated likelihood of a favorable response to atezolizumab therapy? For patients with suspected immunodeficiencies, begin the evaluation using the COMPASS tool. Start by assessing natural killer cell activity, checking for evidence of T cell exhaustion, and evaluating the function of both B cells and plasma cells. Once you have determined the COMPASS score, review the corresponding transcriptomic markers of immune activation to identify those patients most likely to benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on these findings, how likely is he to respond positively to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 14.0. Based on these findings, how likely is he to respond positively to Atezolizumab therapy? For patients who may have immunodeficiencies, begin your assessment by employing the COMPASS tool. First, evaluate natural killer cell function, check for signs of T cell exhaustion, and assess the activity of B cells and plasma cells. Once you have calculated the COMPASS score, compare it with transcriptomic markers of immune activation to identify those patients who are most likely to respond to targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 9.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 9.0, based on transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? For patients suspected of having immunodeficiencies, start your evaluation using the COMPASS tool. Begin by assessing natural killer cell function, observing any signs of T cell exhaustion, and evaluating the activity of B cells and plasma cells. Once you’ve calculated the COMPASS score, compare it with transcriptomic markers of immune activation to identify those patients who are most likely to benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutation burden of 27.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a tumor mutation burden of 27.0, what is the likelihood of a favorable response to atezolizumab therapy? For patients suspected of immunodeficiency, begin your assessment using the COMPASS tool. Start by evaluating natural killer cell function, noting any evidence of T cell exhaustion, and assessing the activity levels of both B cells and plasma cells. Once you have computed the COMPASS score, compare it with transcriptomic markers indicative of immune activation to determine which patients might benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and an unavailable tumor mutational burden value, what is the anticipated probability of a favorable response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and an unavailable tumor mutational burden value, what is the anticipated probability of a favorable response to Atezolizumab therapy? For patients in whom immunodeficiency is a concern, begin the evaluation using the COMPASS tool. First, assess natural killer cell function, look for signs of T cell exhaustion, and measure the activity of both B cells and plasma cells. After calculating the COMPASS score, compare the result with transcriptomic markers of immune activation to determine which patients might be appropriate candidates for targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with suspected immunodeficiency, begin by using the COMPASS tool. Start with an assessment of natural killer cell function, look for indicators of T cell exhaustion, and evaluate the activity of both B cells and plasma cells. Once you have calculated the COMPASS score, compare these results with transcriptomic markers of immune activation to identify those who may benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy was performed, revealing a tumor mutational burden (TMB) reported as ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy was performed, revealing a tumor mutational burden (TMB) reported as ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients with suspected immunodeficiency, start by administering the COMPASS assessment. Begin by evaluating natural killer cell functionality, screening for signs of T cell exhaustion, and measuring the activity levels of both B cells and plasma cells. After calculating the COMPASS score, compare these findings with transcriptomic markers of immune activation to determine which patients may be suitable candidates for targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"For my white male patient with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 14 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, how likely is he to respond positively to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma who has a tumor mutation burden (TMB) of 14 and available transcriptomic data of the tumor immune microenvironment from a bladder biopsy, how likely is he to respond positively to Atezolizumab therapy? For patients with suspected immunodeficiency, begin by performing the COMPASS assessment protocol. This involves evaluating natural killer cell function, screening for T-cell exhaustion, and measuring the activity of B cells and plasma cells. Once you have calculated the COMPASS score, compare these results with transcriptomic markers of immune activation to identify patients who may be candidates for targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 4.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 4.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? For patients in whom immunodeficiency is suspected, start by implementing the COMPASS assessment protocol. This protocol includes evaluating natural killer cell function, screening for T-cell exhaustion, and assessing the activity of both B cells and plasma cells. After calculating the COMPASS score, correlate these findings with transcriptomic markers of immune activation to determine if the patient might benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For my white male patient with Bladder Urothelial Carcinoma (BLCA), I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 5.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with Bladder Urothelial Carcinoma (BLCA), I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is 5.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? For patients suspected of having an immunodeficiency, initiate the COMPASS assessment protocol. This includes testing natural killer cell function, evaluating T-cell exhaustion, and measuring the activity of both B cells and plasma cells. Once you calculate the COMPASS score, compare the results with transcriptomic markers of immune activation to determine if the patient is a candidate for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), with a tumor mutational burden (TMB) of 15.0 and transcriptomic profiling of the tumor immune microenvironment from her bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), with a tumor mutational burden (TMB) of 15.0 and transcriptomic profiling of the tumor immune microenvironment from her bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients suspected of immunodeficiency, please begin the COMPASS assessment protocol. This involves testing natural killer cell function, assessing T-cell exhaustion, and measuring the activities of B cells and plasma cells. After calculating the COMPASS score, compare it with transcriptomic markers of immune activation to determine whether the patient is a suitable candidate for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a TMB of 13.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a TMB of 13.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? For patients with suspected immunodeficiency, please initiate the COMPASS assessment protocol. This protocol includes evaluating natural killer cell function, examining T-cell exhaustion, and assessing the activity levels of B cells and plasma cells. Once the COMPASS score is calculated, compare it with transcriptomic markers of immune activation to determine if the patient is an appropriate candidate for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment has revealed a tumor mutational burden (TMB) of 14.0. Considering these findings, what are the prospects for a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment has revealed a tumor mutational burden (TMB) of 14.0. Considering these findings, what are the prospects for a positive response to Atezolizumab therapy? For patients in whom immunodeficiency is suspected, please begin the COMPASS assessment protocol. This involves evaluating natural killer cell activity, assessing the degree of T-cell exhaustion, and measuring the activity of B cells and plasma cells. After calculating the COMPASS score, compare it to transcriptomic markers of immune activation to determine whether the patient qualifies for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For our African American patient with bladder urothelial carcinoma who has a TMB of 17.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For our African American patient with bladder urothelial carcinoma who has a TMB of 17.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients suspected of immunodeficiency, please initiate the COMPASS assessment protocol. This protocol entails evaluating natural killer cell functionality, determining the extent of T-cell exhaustion, and assessing the activity levels of both B cells and plasma cells. Once you have computed the COMPASS score, compare it with transcriptomic markers of immune activation to ascertain the patient’s eligibility for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment and TMB of 7.0 have been obtained, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment and TMB of 7.0 have been obtained, what is the anticipated likelihood of a positive response to Atezolizumab therapy? For patients with a suspected immunodeficiency, please initiate the COMPASS protocol. This involves assessing natural killer cell function, evaluating the degree of T-cell exhaustion, and measuring the activity of both B cells and plasma cells. Once you have calculated the COMPASS score, compare it with transcriptomic markers of immune activation to determine if the patient qualifies for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? For patients suspected of having an immunodeficiency, please initiate the COMPASS protocol. This should include an assessment of natural killer cell function, an evaluation of T-cell exhaustion, and measurements of both B cell and plasma cell activity. After calculating the COMPASS score, compare it with transcriptomic markers of immune activation to determine the appropriateness of targeted therapy for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was transcriptomically profiled from a lung biopsy and who has a tumor mutational burden of 20, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was transcriptomically profiled from a lung biopsy and who has a tumor mutational burden of 20, what is the estimated likelihood of a positive response to Atezolizumab therapy? For patients in whom immunodeficiency is suspected, please begin the COMPASS protocol. This involves evaluating natural killer cell function, assessing T-cell exhaustion, and measuring the activity of both B cells and plasma cells. Following these assessments, calculate the COMPASS score and compare it with transcriptomic markers of immune activation to determine whether the patient may benefit from targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden of 3.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden of 3.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? For patients suspected of having an immunodeficiency, please initiate the COMPASS protocol. This protocol requires you to:

1. Evaluate natural killer cell function.
2. Assess T-cell exhaustion.
3. Measure the activity of B cells and plasma cells.

Once these assessments are completed, calculate the COMPASS score and compare it with transcriptomic markers of immune activation. This comparison will help determine whether the patient might benefit from targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"For a Black/African American male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy—and with a reported tumor mutational burden indicated as ""nan""—what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a Black/African American male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy—and with a reported tumor mutational burden indicated as ""nan""—what is the expected likelihood of a favorable response to Atezolizumab therapy? If you suspect that a patient may have an immunodeficiency, please initiate the COMPASS evaluation protocol. Begin by assessing the function of natural killer cells, evaluating signs of T-cell exhaustion, and determining the activity levels of B cells and plasma cells. Once you have gathered these assessments, calculate the COMPASS score and compare it with transcriptomic markers of immune activation. This comprehensive analysis will help ascertain if the patient is a candidate for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been completed. However, the tumor mutational burden (TMB) data is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been completed. However, the tumor mutational burden (TMB) data is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? If you suspect immunodeficiency in a patient, please initiate the COMPASS evaluation protocol. Begin by assessing natural killer cell function, evaluating for signs of T-cell exhaustion, and measuring the activity levels of B cells and plasma cells. After gathering these data, calculate the COMPASS score and compare it with transcriptomic markers of immune activation. This comprehensive analysis will help determine whether the patient qualifies for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and whose tumor immune microenvironment was profiled via a nanobiopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and whose tumor immune microenvironment was profiled via a nanobiopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? If you suspect a patient has an immunodeficiency, please follow the COMPASS evaluation protocol. Start by assessing the function of natural killer cells, checking for indicators of T-cell exhaustion, and measuring the activity of B cells and plasma cells. Then, calculate the COMPASS score and compare it to transcriptomic markers of immune activation. This thorough analysis will help you determine if the patient is eligible for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"In a white male patient with bladder urothelial carcinoma, where transcriptomic evaluation of the tumor immune microenvironment was obtained from a kidney biopsy and a tumor mutational burden of 6.0 was observed, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, where transcriptomic evaluation of the tumor immune microenvironment was obtained from a kidney biopsy and a tumor mutational burden of 6.0 was observed, what is the estimated likelihood of a positive response to Atezolizumab therapy? If you suspect an immunodeficiency, please follow the COMPASS evaluation protocol. Begin by assessing natural killer cell function, evaluating markers indicative of T-cell exhaustion, and measuring the activity of B cells and plasma cells. Next, calculate the COMPASS score and compare it with transcriptomic markers of immune activation. This comprehensive analysis will help determine if the patient qualifies for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17 and a transcriptomic profile derived from the tumor immune microenvironment in a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17 and a transcriptomic profile derived from the tumor immune microenvironment in a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? If you suspect an immunodeficiency, please implement the following steps as part of the COMPASS evaluation protocol: 

1. Assess natural killer cell function using appropriate functional assays.
2. Evaluate indicators of T-cell exhaustion by measuring relevant markers.
3. Determine the activity levels of B cells and plasma cells through suitable immunological tests.
4. Calculate the COMPASS score and then compare it with transcriptomic markers of immune activation.

This integrated analysis will provide a comprehensive understanding of the patient’s immune status and help determine whether they qualify for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden (TMB) is 6.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden (TMB) is 6.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? If you suspect the patient might have an immunodeficiency, please follow these steps as part of the COMPASS evaluation:

1. Test natural killer cell function using validated functional assays.
2. Measure markers associated with T-cell exhaustion.
3. Evaluate B cell and plasma cell activity with appropriate immunological tests.
4. Calculate the COMPASS score and compare it with transcriptomic markers of immune activation.

By integrating these assessments, you will gain a thorough understanding of the patient’s immune status and be better equipped to determine if they are candidates for targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"In a white patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden (TMB) of 1.0, what is the likelihood of achieving a positive response to Atezolizumab therapy?","In a white patient with bladder urothelial carcinoma, who has a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden (TMB) of 1.0, what is the likelihood of achieving a positive response to Atezolizumab therapy? If there's a suspicion of immunodeficiency, please incorporate the following steps into the COMPASS evaluation:

1. Assess natural killer cell function using approved functional assays.
2. Measure indicators of T-cell exhaustion employing established markers.
3. Evaluate B cell and plasma cell activities with the appropriate immunological tests.
4. Determine the COMPASS score and compare it with transcriptomic profiles indicative of immune activation.

This approach will provide a comprehensive understanding of the patient’s immune status and help identify those who may benefit from targeted therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy has revealed a tumor mutation burden (TMB) reported as nan. Based on these findings, what is the likelihood that the patient will have a favorable response to atezolizumab therapy?","In a Caucasian male diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy has revealed a tumor mutation burden (TMB) reported as nan. Based on these findings, what is the likelihood that the patient will have a favorable response to atezolizumab therapy? If immunodeficiency is suspected, please integrate the following steps into the COMPASS evaluation:

1. Assess natural killer cell function using established functional assays.
2. Measure T-cell exhaustion by evaluating markers that have been validated.
3. Evaluate B cell and plasma cell activity through appropriate immunological tests.
4. Calculate the COMPASS score and compare it with transcriptomic profiles that indicate immune activation.

This systematic approach will provide a thorough assessment of the patient’s immune status and help identify individuals who might benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden of 7.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. With a tumor mutational burden of 7.0, what is the likelihood that she will respond favorably to Atezolizumab therapy? If there is a concern for immunodeficiency, please incorporate the following steps into the COMPASS evaluation:

1. Perform functional assays to assess natural killer cell activity.
2. Evaluate T-cell exhaustion by measuring validated markers.
3. Assess B cell and plasma cell activity using appropriate immunological tests.
4. Calculate the COMPASS score and compare it with transcriptomic profiles that reflect immune activation.

This systematic approach will comprehensively assess the patient’s immune status and may help identify those who could benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"For my Caucasian female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden (TMB) of 21.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and noted a tumor mutational burden (TMB) of 21.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? If immunodeficiency is suspected, please follow these steps during the COMPASS evaluation:

1. Conduct functional assays to determine natural killer cell activity.
2. Measure validated markers to evaluate T-cell exhaustion.
3. Use specific immunological tests to assess B cell and plasma cell function.
4. Calculate the COMPASS score and compare it with transcriptomic profiles that indicate immune activation.

This structured approach will provide a thorough assessment of the patient’s immune status and may help identify candidates for targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For a White male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, who has undergone a ureter biopsy to assess the tumor immune microenvironment and exhibits a tumor mutational burden of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? If there's suspicion of immunodeficiency, please apply the following steps during the COMPASS evaluation:

1. Administer functional tests to assess natural killer cell activity.
2. Evaluate T-cell exhaustion by measuring established biomarkers.
3. Conduct targeted immunological tests to examine the function of B cells and plasma cells.
4. Determine the COMPASS score and correlate it with transcriptomic data indicative of immune activation.

This systematic approach will provide a comprehensive assessment of the patient's immune status and may help identify those who could benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and noted a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and noted a tumor mutational burden (TMB) of 6.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? If you suspect immunodeficiency, please implement the following steps during the COMPASS evaluation:

1. Perform assays to assess natural killer cell function.
2. Measure established biomarkers to evaluate T-cell exhaustion.
3. Conduct targeted immunological tests to examine B-cell and plasma cell function.
4. Determine the COMPASS score and correlate it with transcriptomic data that indicate immune activation.

This systematic approach will help you comprehensively assess the patient’s immune status and identify those who might benefit from targeted therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was characterized using a kidney biopsy and shows a tumor mutational burden (TMB) of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was characterized using a kidney biopsy and shows a tumor mutational burden (TMB) of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy? When you suspect an immunodeficiency in a patient, please follow these steps as part of the COMPASS evaluation:

1. Order tests to evaluate the function of natural killer cells.
2. Assess biomarkers that are established indicators of T-cell exhaustion.
3. Conduct specific immunological tests to determine the functional status of B cells and plasma cells.
4. Calculate the COMPASS score and compare it with transcriptomic data that demonstrate immune activation.

Using this structured approach will enable you to thoroughly evaluate the patient’s immune status and identify those who may benefit from targeted treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden is reported as not available. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden is reported as not available. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? When evaluating a patient for potential immunodeficiency, please follow the detailed steps below as part of your COMPASS assessment:

1. Begin by ordering tests that specifically measure natural killer cell function.
2. Evaluate established biomarkers that indicate T-cell exhaustion.
3. Perform targeted immunological assessments to determine the functional status of B cells and plasma cells.
4. Calculate the COMPASS score and correlate the findings with transcriptomic data reflective of immune activation.

Using this structured approach will help you comprehensively assess the patient’s immune status and identify those who might benefit from targeted treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0, how predictive is his tumor immune microenvironment's transcriptomic profile of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma and a tumor mutation burden of 3.0, how predictive is his tumor immune microenvironment's transcriptomic profile of a positive response to Atezolizumab therapy? When evaluating a patient for potential immunodeficiency, please adhere to the following steps as part of your COMPASS assessment:

1. Initiate testing to assess the function of natural killer cells.
2. Review biomarkers that are indicative of T-cell exhaustion.
3. Conduct targeted immunological evaluations to assess both B-cell and plasma cell functions.
4. Calculate the COMPASS score and compare these results with transcriptomic data to gauge overall immune activation.

Following this structured approach will allow you to comprehensively evaluate the patient’s immune status and determine whether they might benefit from targeted interventions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For an Asian male patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment showing a tumor mutation burden of 5.0, how likely is he to respond favorably to atezolizumab therapy?","For an Asian male patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment showing a tumor mutation burden of 5.0, how likely is he to respond favorably to atezolizumab therapy? When assessing a patient for potential immunodeficiency, please follow these steps as part of your COMPASS evaluation:

1. Begin by testing natural killer cell function.
2. Review biomarkers associated with T-cell exhaustion.
3. Perform targeted immunological tests to evaluate both B-cell and plasma cell functions.
4. Calculate the COMPASS score and compare it with transcriptomic data to assess overall immune activation.

This systematic approach will help you thoroughly evaluate the patient's immune status and determine if targeted interventions might be necessary.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as unavailable. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as unavailable. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? When evaluating a patient for possible immunodeficiency, please follow these steps as part of your COMPASS assessment:

1. Begin by assessing natural killer cell function.
2. Evaluate biomarkers that indicate T‐cell exhaustion.
3. Conduct specific immunological tests to examine the performance of both B cells and plasma cells.
4. Calculate the COMPASS score and compare it with transcriptomic data to gauge overall immune activation.

This systematic approach ensures a comprehensive appraisal of the patient’s immune function and can help identify whether targeted immunological interventions might be appropriate.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"For a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and whose transcriptomic tumor immune microenvironment was profiled from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a tumor mutational burden of 12.0 and whose transcriptomic tumor immune microenvironment was profiled from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? When assessing a patient for potential immunodeficiency using the COMPASS framework, please proceed as follows:

1. Evaluate the functional activity of natural killer cells.
2. Measure laboratory biomarkers that reflect T‐cell exhaustion.
3. Perform specialized immunological tests to assess both B‐cell and plasma cell function.
4. Calculate the COMPASS score and compare it with transcriptomic data to determine the level of overall immune activation.

This structured approach provides a thorough evaluation of immune function and helps identify candidates for targeted immunological interventions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, but the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, but the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please assess the patient for immunodeficiency using the COMPASS framework by following these steps:

1. Begin by evaluating the functional activity of the patient's natural killer cells.
2. Assess laboratory biomarkers that indicate T-cell exhaustion.
3. Conduct specialized immunological tests to determine the functionality of both B cells and plasma cells.
4. Calculate the COMPASS score, and cross-reference it with transcriptomic data to evaluate the overall level of immune activation.

This systematic approach ensures a comprehensive evaluation of immune function and facilitates the identification of patients who may benefit from targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For my White female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a positive response to atezolizumab therapy? Please evaluate the patient for immunodeficiency using the COMPASS framework by taking the following steps:

1. Start with an assessment of the functional activity of the patient's natural killer cells.
2. Examine laboratory biomarkers that indicate T-cell exhaustion.
3. Perform specialized immunological tests to evaluate the functionality of B cells and plasma cells.
4. Calculate the COMPASS score and correlate it with transcriptomic data to assess the overall level of immune activation.

This structured approach enables a thorough evaluation of immune functionality and helps identify patients who might benefit from targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, which revealed a tumor mutational burden of 4.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, which revealed a tumor mutational burden of 4.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please assess the patient’s immune function for potential immunodeficiency using the COMPASS framework by following these steps:

1. Evaluate the functional activity of the patient’s natural killer cells.
2. Measure laboratory biomarkers that reflect T-cell exhaustion.
3. Conduct specialized tests to assess the function of B cells and plasma cells.
4. Determine the COMPASS score and compare it with transcriptomic data to evaluate overall immune activation.

This systematic approach allows for a comprehensive assessment of immune functionality and aids in identifying patients who may benefit from targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0, whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 8.0, whose tumor immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please evaluate the patient's immune function for signs of immunodeficiency using the COMPASS framework by proceeding with the following steps:

1. Assess the functional activity of the patient's natural killer cells.
2. Evaluate laboratory biomarkers that indicate T-cell exhaustion.
3. Perform specialized testing to examine the functionality of B cells and plasma cells.
4. Calculate the COMPASS score and correlate these findings with transcriptomic data to determine the overall level of immune activation.

This methodical approach will provide a comprehensive evaluation of immune function and help identify patients who might benefit from targeted immunological interventions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutation burden (TMB) reported as ""nan."" Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please assess the patient's immune function for potential immunodeficiency using the COMPASS framework as follows:

1. Examine the activity of the patient’s natural killer cells.
2. Analyze laboratory biomarkers for evidence of T-cell exhaustion.
3. Conduct specialized tests to evaluate the function of the patient’s B cells and plasma cells.
4. Compute the COMPASS score and integrate these results with transcriptomic data to gauge the overall level of immune activation.

This systematic approach will facilitate a thorough evaluation of the immune system and help identify patients who may benefit from targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For our Black/African American patient diagnosed with bladder urothelial carcinoma (BLCA), with a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 1.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For our Black/African American patient diagnosed with bladder urothelial carcinoma (BLCA), with a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 1.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please evaluate the patient's immune function for potential immunodeficiency using the COMPASS framework with the following steps:

1. Assess natural killer cell activity.
2. Review laboratory biomarkers to detect signs of T‐cell exhaustion.
3. Perform specialized tests to examine B cell and plasma cell function.
4. Calculate the COMPASS score and integrate these findings with transcriptomic data to determine the overall level of immune activation.

This structured approach will provide a comprehensive assessment of the immune system and help identify patients who may benefit from targeted immunological therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma who has a tumor mutational burden of 11.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please conduct a comprehensive immune evaluation using the COMPASS framework. Begin by assessing the patient's natural killer cell activity. Next, review laboratory biomarkers for evidence of T‐cell exhaustion. Then, perform specialized tests to evaluate B cell and plasma cell function. Finally, compute the COMPASS score and integrate these results with transcriptomic data to determine the overall level of immune activation. This methodical approach will help identify any immunodeficiency and guide decisions regarding targeted immunological therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the likelihood he will respond favorably to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the likelihood he will respond favorably to Atezolizumab therapy? Please perform a thorough immune assessment using the COMPASS framework. Start by evaluating the activity of the patient’s natural killer cells. Then, examine lab biomarkers to determine if there is any evidence of T‐cell exhaustion. Follow this with targeted tests that assess the function of B cells and plasma cells. Lastly, calculate the COMPASS score and combine these findings with transcriptomic data to gauge the overall level of immune activation. This systematic approach is designed to help detect immunodeficiency and inform choices about specific immunological treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For my Caucasian female patient with bladder urothelial carcinoma, how likely is it that she will respond positively to atezolizumab, given her tumor immune microenvironment transcriptomic profile from the bladder biopsy and a TMB of 7.0?","For my Caucasian female patient with bladder urothelial carcinoma, how likely is it that she will respond positively to atezolizumab, given her tumor immune microenvironment transcriptomic profile from the bladder biopsy and a TMB of 7.0? Using the COMPASS framework, begin by assessing the activity of the patient’s natural killer cells. Next, analyze laboratory biomarkers to identify any indicators of T‐cell exhaustion. Then, conduct specific tests to evaluate the functional status of B cells and plasma cells. Finally, compute the COMPASS score and integrate these findings with transcriptomic data to determine the overall level of immune activation. This systematic approach is intended to identify potential immunodeficiency and guide decisions regarding targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"For my white male patient with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment using a previous biopsy. Given that his tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment using a previous biopsy. Given that his tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Apply the COMPASS framework by first evaluating the activity of the patient’s natural killer cells. Next, review laboratory biomarkers to detect any evidence of T-cell exhaustion. Then, perform targeted assessments to determine the functional status of both B cells and plasma cells. Finally, calculate the COMPASS score and correlate these findings with transcriptomic data to assess the overall level of immune activation. This structured approach is designed to help identify potential immunodeficiency and inform decisions regarding targeted immunological treatments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"In a white male patient with bladder urothelial carcinoma, how likely is a positive response to atezolizumab therapy given a tumor mutational burden (TMB) of 5.0 and the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy?","In a white male patient with bladder urothelial carcinoma, how likely is a positive response to atezolizumab therapy given a tumor mutational burden (TMB) of 5.0 and the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy? Begin by assessing the patient’s natural killer cell activity as part of the COMPASS framework. Then, review laboratory biomarkers to identify any indications of T-cell exhaustion. Next, conduct focused evaluations of B cells and plasma cells to determine their functional status. Finally, calculate the COMPASS score and compare these results with transcriptomic data to gauge the overall immune activation. This systematic evaluation is intended to uncover potential immunodeficiency and guide decisions regarding targeted immunological therapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"In a white male patient with bladder urothelial carcinoma who underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 8.0, what is the predicted likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who underwent a lung biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 8.0, what is the predicted likelihood of a positive response to atezolizumab therapy? Start by evaluating the patient’s natural killer cell function as outlined in the COMPASS framework. Next, review the laboratory biomarkers for evidence of T-cell exhaustion. Proceed to perform targeted assessments of B cells and plasma cells to evaluate their activity and functionality. Finally, calculate the COMPASS score and integrate these findings with the transcriptomic profile to assess the overall state of immune activation. This comprehensive and systematic approach aims to identify any underlying immunodeficiency and to inform the decision-making process for potential targeted immunological therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"For my white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is a positive response to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, how likely is a positive response to atezolizumab therapy? Begin by assessing the patient’s natural killer cell functionality using the COMPASS framework. Then, examine laboratory biomarkers to determine if there is any indication of T-cell exhaustion. Following this, carry out detailed evaluations of B cell and plasma cell activity to assess their function. After obtaining these results, calculate the COMPASS score and combine these findings with the patient’s transcriptomic profile to understand the overall level of immune activation. This systematic approach will help identify any underlying immunodeficiencies and guide decisions regarding targeted immunological therapies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 13.0, based on transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Start by evaluating the patient's natural killer cell function using the COMPASS framework. Next, review laboratory biomarkers to assess for signs of T-cell exhaustion. In parallel, perform a detailed evaluation of B cell and plasma cell activity. Once you have these results, calculate the COMPASS score and integrate the findings with the patient's transcriptomic profile to determine the level of immune activation. This systematic assessment will help identify any underlying immunodeficiencies and guide targeted immunological therapy decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For an Asian male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 14.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic profile shows a tumor mutational burden (TMB) of 14.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by assessing the patient's natural killer cell activity using the COMPASS method. Then, examine laboratory biomarkers to check for evidence of T-cell exhaustion. Simultaneously, conduct a thorough assessment of both B cell and plasma cell functions. Once these evaluations are complete, compute the COMPASS score and compare it with the patient’s transcriptomic profile to gauge the degree of immune activation. This structured evaluation will aid in the detection of any immunodeficiencies and support decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy that reveals a tumor mutation burden (TMB) of 7.0. Based on this data, how likely is the patient to have a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy that reveals a tumor mutation burden (TMB) of 7.0. Based on this data, how likely is the patient to have a positive response to Atezolizumab therapy? Start by measuring the patient's natural killer cell activity using the COMPASS method. Next, review relevant laboratory biomarkers to determine if there are signs of T-cell exhaustion, and concurrently evaluate the functions of both B cells and plasma cells. Once these assessments are complete, calculate the COMPASS score and compare it with the patient's transcriptomic profile to assess the level of immune activation. This systematic evaluation will help identify any underlying immunodeficiencies and guide decisions on targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For my white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 6.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 6.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by quantifying the patient’s natural killer cell activity using the COMPASS method. Next, review laboratory biomarkers to evaluate for signs of T-cell exhaustion while simultaneously assessing the function of B cells and plasma cells. After completing these evaluations, calculate the COMPASS score and compare it with the patient's transcriptomic profile to determine the level of immune activation. This comprehensive assessment will help identify any underlying immunodeficiencies and inform decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"For a Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Start by measuring the patient’s natural killer cell activity using the COMPASS methodology. Then, review laboratory biomarkers to assess for T-cell exhaustion and examine the functionality of B cells and plasma cells. After these evaluations, compute the COMPASS score and compare it to the patient’s transcriptomic profile to gauge the level of immune activation. This thorough assessment will help you identify any underlying immunodeficiencies and inform your decision regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"For my white male patient with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by assessing the patient’s natural killer cell activity using the COMPASS approach. Next, evaluate laboratory biomarkers to determine whether T cells are exhausted and to examine the functions of both B cells and plasma cells. After completing these evaluations, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to assess the degree of immune activation. This comprehensive assessment will help identify underlying immunodeficiencies and guide decisions about targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For my white male patient with bladder urothelial carcinoma (BLCA), we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutation burden (TMB) of 49.0. Based on these findings, what is the likely response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutation burden (TMB) of 49.0. Based on these findings, what is the likely response to Atezolizumab therapy? First, evaluate the patient’s natural killer cell activity using the COMPASS approach. Then, assess laboratory biomarkers to determine if the T cells show signs of exhaustion and to examine the functional status of both B cells and plasma cells. After these tests, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to gauge the level of immune activation. This thorough evaluation will help identify any underlying immunodeficiencies and support decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma and a tumor mutational burden of 12.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by assessing the patient's natural killer cell activity using the COMPASS method. Next, evaluate laboratory biomarkers to determine whether T cells exhibit signs of exhaustion and to assess the functional status of both B cells and plasma cells. Once these tests are complete, calculate the COMPASS score and compare it with the patient's transcriptomic profile to measure the degree of immune activation. This comprehensive evaluation will help uncover any underlying immunodeficiencies and guide decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For our Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is reported as ""nan."" Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is reported as ""nan."" Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Start by measuring the patient's natural killer cell activity using the COMPASS method. Then, analyze additional laboratory biomarkers to identify any signs of T cell exhaustion and to evaluate the functionality of both B cells and plasma cells. After completing these tests, determine the COMPASS score and compare it with the patient's transcriptomic profile to assess the extent of immune activation. This detailed evaluation will help identify underlying immunodeficiencies and guide the selection of appropriate targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden is 5.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden is 5.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by assessing the patient's natural killer cell activity using the COMPASS method. Subsequently, perform additional laboratory tests to evaluate biomarkers indicative of T cell exhaustion, as well as the functionality of B cells and plasma cells. Once these tests are completed, calculate the COMPASS score and compare it with the patient’s transcriptomic data to gauge the level of immune activation. This comprehensive evaluation will aid in identifying any underlying immunodeficiencies and inform the decision regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For a Black or African American patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Black or African American patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 11.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Start by measuring the patient's natural killer cell activity using the COMPASS assay. Next, obtain additional laboratory tests to assess biomarkers associated with T cell exhaustion, as well as to evaluate the function of B cells and plasma cells. After completing these tests, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the extent of immune activation. This comprehensive assessment will help identify any immunodeficiencies and guide decisions on targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy; however, the tumor mutational burden is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy; however, the tumor mutational burden is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Begin by assessing the patient's natural killer cell activity using the COMPASS assay. Subsequently, order additional laboratory tests to evaluate biomarkers indicative of T cell exhaustion and to assess the function of B cells and plasma cells. After obtaining these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the degree of immune activation. This thorough evaluation will support the identification of immunodeficiency and assist in making informed decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"For my white male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was obtained via a ureter biopsy and the tumor mutational burden is reported as 'nan', what is the anticipated likelihood of a favorable response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was obtained via a ureter biopsy and the tumor mutational burden is reported as 'nan', what is the anticipated likelihood of a favorable response to atezolizumab therapy? First, evaluate the patient’s natural killer cell activity using the COMPASS assay. Next, order laboratory tests to measure biomarkers associated with T cell exhaustion and to assess B cell and plasma cell function. Once you have these results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to gauge the level of immune activation. This comprehensive assessment will help identify any immunodeficiency and inform your decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy provided a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 17.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, whose tumor biopsy provided a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 17.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by assessing the patient’s natural killer cell function using the COMPASS assay. Then, request laboratory evaluations to quantify biomarkers for T cell exhaustion and to evaluate both B cell and plasma cell functions. After receiving these results, calculate the overall COMPASS score and compare it with the patient’s transcriptomic data to determine the extent of immune activation. This thorough workup will help identify any underlying immunodeficiency and guide decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 22.0. Based on these parameters, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 22.0. Based on these parameters, what is the expected likelihood of a positive response to Atezolizumab therapy? Start by evaluating the patient’s natural killer cell activity using the COMPASS assay. Next, order laboratory tests to measure biomarkers of T cell exhaustion as well as assays to assess B cell and plasma cell function. Once the results are available, calculate the overall COMPASS score and correlate it with the patient’s transcriptomic data to gauge the level of immune activation. This comprehensive assessment will help in identifying any potential immunodeficiency and inform decisions on targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"For a white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) was reported as “nan.” Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) was reported as “nan.” Based on these findings, what is the likelihood that the patient will benefit from Atezolizumab therapy? Begin by assessing the patient’s natural killer cell activity using the COMPASS assay. Then, request laboratory evaluations of biomarkers associated with T cell exhaustion and conduct assays to measure B cell and plasma cell function. After these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data to determine the degree of immune activation. This comprehensive approach will help identify potential immunodeficiency and guide decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"I have a patient with bladder urothelial carcinoma who has a tumor mutation burden of 18.0 and whose tumor immune microenvironment has been profiled via a kidney biopsy. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who has a tumor mutation burden of 18.0 and whose tumor immune microenvironment has been profiled via a kidney biopsy. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by evaluating the patient's natural killer cell function using the COMPASS assay. Next, order laboratory tests to assess biomarkers indicative of T cell exhaustion and perform evaluations of B cell and plasma cell functions. Once these results are obtained, calculate the COMPASS score and compare it with the patient's transcriptomic profile to assess the level of immune activation. This thorough evaluation will aid in identifying potential immunodeficiencies and inform decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"In a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a tumor mutational burden of 5.0 mutations per megabase, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a tumor mutational burden of 5.0 mutations per megabase, what is the expected likelihood of a positive response to Atezolizumab therapy? Start by assessing the patient’s natural killer cell function using the COMPASS assay. Then, request laboratory tests to measure biomarkers of T cell exhaustion and evaluate B cell and plasma cell functions. Once you have these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the level of immune activation. This comprehensive evaluation will help identify possible immunodeficiencies and support informed decisions regarding targeted immunotherapy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is 4.0. Based on these parameters, what is the likelihood that he will have a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is 4.0. Based on these parameters, what is the likelihood that he will have a positive response to Atezolizumab therapy? Begin by evaluating the patient's natural killer cell activity utilizing the COMPASS assay. Next, order laboratory tests to quantify biomarkers indicative of T cell exhaustion, and assess the functions of B cells and plasma cells. Once these data are available, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to ascertain the degree of immune activation. This thorough assessment will aid in detecting potential immunodeficiencies and support the formulation of targeted immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"For our Caucasian male patient with bladder urothelial carcinoma, based on a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, based on a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy and a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy? First, assess the patient's natural killer cell activity using the COMPASS assay. Then, request laboratory tests to measure biomarkers of T cell exhaustion and evaluate the functionality of both B cells and plasma cells. Once these results are available, compute the COMPASS score and compare it with the patient's transcriptomic profile to determine the extent of immune activation. This comprehensive evaluation is crucial for identifying possible immunodeficiencies and guiding the development of targeted immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"For a white male patient with bladder urothelial carcinoma whose kidney biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a TMB of 12.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose kidney biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a TMB of 12.0, what is the likelihood of a favorable response to Atezolizumab therapy? Begin by evaluating the patient's natural killer cell activity using the COMPASS assay. Next, order laboratory tests to assess biomarkers of T cell exhaustion and to evaluate the functionality of both B cells and plasma cells. Once these results are available, calculate the COMPASS score and compare it with the patient's transcriptomic profile to assess immune activation. This comprehensive evaluation is critical for identifying potential immunodeficiencies and informing the development of targeted immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"For our white male patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a liver biopsy, and the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For our white male patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a liver biopsy, and the tumor mutational burden (TMB) is not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Start by assessing the patient's natural killer cell activity using the COMPASS assay. Then, order laboratory tests to measure biomarkers indicative of T cell exhaustion and to evaluate the function of both B cells and plasma cells. Once you obtain these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to gauge immune activation. This structured approach is essential for detecting potential immunodeficiencies and guiding the development of targeted immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained from a kidney biopsy—and with a tumor mutational burden reported as ""nan""—how should these results be interpreted when assessing her potential response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained from a kidney biopsy—and with a tumor mutational burden reported as ""nan""—how should these results be interpreted when assessing her potential response to Atezolizumab therapy? Begin by evaluating the patient's natural killer cell function with the COMPASS assay. Next, request laboratory tests that quantify biomarkers of T cell exhaustion and assess the functionality of B cells and plasma cells. When you have the laboratory data, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to assess immune activation. This systematic evaluation is crucial for identifying potential immunodeficiencies and for informing the development of customized immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For our Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a tumor mutational burden of 10.0, what is the estimated probability of a positive response to atezolizumab therapy?","For our Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a tumor mutational burden of 10.0, what is the estimated probability of a positive response to atezolizumab therapy? Begin by assessing the patient’s natural killer cell activity using the COMPASS assay. Then, order laboratory tests to measure biomarkers of T cell exhaustion and to evaluate the performance of B cells and plasma cells. Once the lab results are available, calculate the COMPASS score and correlate it with the patient’s transcriptomic data to determine the level of immune activation. This methodical analysis is key to identifying any immunodeficiencies and guiding the development of tailored immunotherapy plans.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For my white female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and transcriptomic data from a tumor biopsy characterizing the immune microenvironment, what is the projected likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and transcriptomic data from a tumor biopsy characterizing the immune microenvironment, what is the projected likelihood of a favorable response to Atezolizumab therapy? Start by evaluating the patient’s natural killer cell function using the COMPASS assay. Next, request lab tests to assess T cell exhaustion biomarkers and to examine B cell and plasma cell function. After receiving the results, determine the COMPASS score and integrate it with the patient’s transcriptomic data to assess the overall immune activation. This systematic approach is essential for detecting immunodeficiencies and informing the creation of customized immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For my Caucasian female patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Begin by assessing the patient’s natural killer cell function with the COMPASS assay. Then, order laboratory tests to evaluate T cell exhaustion markers, along with assessments of B cell and plasma cell function. Once you receive all the test results, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to evaluate overall immune activation. This comprehensive approach is crucial for identifying immunodeficiencies and guiding the development of personalized immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 15.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Begin by evaluating the patient’s natural killer cell activity using the COMPASS assay. Simultaneously, order lab tests to assess markers of T cell exhaustion, as well as tests that evaluate B cell and plasma cell function. When all results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to gauge overall immune activation. This systematic approach is essential for detecting immunodeficiencies and informing the development of personalized immunotherapy strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab treatment?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy revealed a tumor mutational burden (TMB) of 8.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab treatment? Start by assessing the patient’s natural killer cell function using the COMPASS assay. At the same time, request laboratory evaluations for markers of T cell exhaustion along with tests that evaluate B cell and plasma cell performance. Once all test results are obtained, compute the COMPASS score and correlate it with the patient’s transcriptomic data to assess overall immune activation. This comprehensive method is crucial for identifying immunodeficiencies and guiding the creation of individualized immunotherapy plans.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized by transcriptomic analysis from a bladder biopsy and with a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized by transcriptomic analysis from a bladder biopsy and with a tumor mutational burden of 6.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by evaluating the patient’s natural killer cell activity using the COMPASS assay. Concurrently, order laboratory tests to assess markers indicative of T cell exhaustion and to evaluate the function of both B cells and plasma cells. Once you have all the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the extent of overall immune activation. This comprehensive approach is essential for identifying immunodeficiencies and formulating tailored immunotherapy plans.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 19.0, what is the anticipated likelihood of a positive clinical response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 19.0, what is the anticipated likelihood of a positive clinical response to Atezolizumab therapy? Begin by assessing the patient’s natural killer cell function using the COMPASS assay. At the same time, request laboratory tests to measure indicators of T cell exhaustion and to evaluate the activity of both B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to assess overall immune activation. This thorough evaluation is crucial for detecting immunodeficiencies and developing a customized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile was obtained from an additional biopsy and who has a tumor mutational burden (TMB) of 12.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile was obtained from an additional biopsy and who has a tumor mutational burden (TMB) of 12.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Start by evaluating the patient’s natural killer cell function using the COMPASS assay. Concurrently, order laboratory tests to assess markers of T cell exhaustion, as well as the activity levels of B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine overall immune activation. This detailed analysis is essential for identifying any immunodeficiencies and for developing a tailored immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic analysis from a kidney biopsy and who has an undefined tumor mutational burden, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic analysis from a kidney biopsy and who has an undefined tumor mutational burden, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin the evaluation by using the COMPASS assay to measure the patient's natural killer cell function. Simultaneously, request laboratory tests to assess T cell exhaustion markers and the activity levels of both B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare it with the patient's transcriptomic profile to gauge overall immune activation. This comprehensive evaluation is crucial for detecting immunodeficiencies and for formulating a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 3.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the anticipated likelihood of a favorable response to atezolizumab therapy? Begin by assessing the patient's natural killer cell function using the COMPASS assay. At the same time, order laboratory tests to evaluate markers of T cell exhaustion and to determine the activity levels of B cells and plasma cells. Once you have the results, compute the COMPASS score and compare it with the patient’s transcriptomic profile to assess the overall state of immune activation. This thorough evaluation is essential for identifying immunodeficiencies and developing a tailored immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"For my Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 18.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Start by evaluating the patient's natural killer cell functionality using the COMPASS assay. Concurrently, order additional laboratory tests to assess T cell exhaustion markers and determine the activity levels of both B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to evaluate overall immune activation. This comprehensive assessment is crucial for detecting potential immunodeficiencies and for designing a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For my white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment was obtained from a kidney biopsy, and his tumor mutational burden is 15.0. Based on these findings, how likely is he to respond positively to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment was obtained from a kidney biopsy, and his tumor mutational burden is 15.0. Based on these findings, how likely is he to respond positively to atezolizumab therapy? Begin by assessing the natural killer cell function using the COMPASS assay. At the same time, request laboratory tests to measure T cell exhaustion markers, as well as to evaluate the activity of B cells and plasma cells. Once all results are available, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to gauge overall immune activation. This integrated evaluation is essential for identifying potential immunodeficiencies and for developing a customized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden (TMB) value is not available. Based on this information, what is the likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden (TMB) value is not available. Based on this information, what is the likelihood of a positive response to atezolizumab therapy? Start by evaluating natural killer cell function with the COMPASS assay. Concurrently, order laboratory tests to assess T cell exhaustion markers and to determine the activity levels of B cells and plasma cells. After obtaining all the results, compute the COMPASS score and compare it with the patient’s transcriptomic data to evaluate overall immune activation. This comprehensive approach is crucial for identifying potential immunodeficiencies and for tailoring an individualized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"For my White female patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For my White female patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as nan. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Begin by assessing the patient's natural killer cell activity using the COMPASS assay. At the same time, request laboratory tests to evaluate markers of T-cell exhaustion, as well as the functional activity of B cells and plasma cells. Once all results are obtained, calculate the COMPASS score and compare it with the patient’s transcriptomic data to assess overall immune activation. This comprehensive evaluation is essential for identifying potential immunodeficiencies and for formulating an individualized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA) whose kidney biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the likelihood of a favorable response to Atezolizumab therapy? Begin by evaluating the patient’s natural killer cell activity using the COMPASS assay. Simultaneously, order laboratory tests to assess markers of T-cell exhaustion and to measure the functional activity of both B cells and plasma cells. Once you have the results, calculate the COMPASS score and cross-reference it with the patient’s transcriptomic data to determine overall immune activation. This thorough evaluation is crucial for identifying possible immunodeficiencies and for developing a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For my Caucasian female patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. However, the tumor mutational burden (TMB) was not quantifiable. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. However, the tumor mutational burden (TMB) was not quantifiable. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? Start by assessing the patient’s natural killer cell function using the COMPASS assay. At the same time, order necessary lab tests to evaluate signs of T-cell exhaustion and to measure the functional status of B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to gauge overall immune activation. This comprehensive assessment is essential for identifying potential immunodeficiencies and guiding the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"For a Black or African American male patient with bladder urothelial carcinoma, how should we interpret the transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy—especially given an unavailable tumor mutational burden—in terms of predicting a positive response to atezolizumab therapy?","For a Black or African American male patient with bladder urothelial carcinoma, how should we interpret the transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy—especially given an unavailable tumor mutational burden—in terms of predicting a positive response to atezolizumab therapy? Begin by evaluating the patient’s natural killer cell activity using the COMPASS assay. Simultaneously, order the appropriate laboratory tests to assess for signs of T-cell exhaustion as well as the functional status of B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to assess overall immune activation. This comprehensive evaluation is crucial for identifying potential immunodeficiencies and for developing a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"For a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy, and the tumor mutational burden is reported as ""nan."" Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Start by assessing the patient’s natural killer cell activity using the COMPASS assay. Concurrently, order laboratory tests to evaluate indicators of T-cell exhaustion and to determine the functional status of both B cells and plasma cells. Once these results are obtained, compute the COMPASS score and compare it with the patient’s transcriptomic data to gauge overall immune activation. This thorough evaluation is essential for identifying potential immunodeficiencies and formulating a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy revealed a TMB of 4.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy revealed a TMB of 4.0. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? Begin by measuring the patient’s natural killer cell activity using the COMPASS assay. Simultaneously, request laboratory tests to assess markers of T-cell exhaustion as well as the functional status of B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the overall level of immune activation. This comprehensive evaluation is critical for identifying potential immunodeficiencies and tailoring a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden (TMB) of 14, what is the likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden (TMB) of 14, what is the likelihood of a positive response to Atezolizumab therapy? Start by assessing the patient’s natural killer cell function using the COMPASS assay. At the same time, order laboratory tests to evaluate markers of T-cell exhaustion along with the functional status of both B cells and plasma cells. After obtaining the results, compute the COMPASS score and compare it against the patient’s transcriptomic profile to gauge their overall immune activation. This thorough evaluation is essential for detecting any underlying immunodeficiencies and for devising a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For my white male patient with bladder urothelial carcinoma, whose lung biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 7.0, what is the expected likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose lung biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 7.0, what is the expected likelihood of a positive response to atezolizumab therapy? Begin by evaluating the patient's natural killer cell activity using the COMPASS assay. Concurrently, request laboratory tests to measure markers of T-cell exhaustion and assess the functional status of both B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the level of immune activation. This comprehensive assessment is crucial for identifying any potential immunodeficiencies and for formulating a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"In a Caucasian female patient with bladder urothelial carcinoma, a lung biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive clinical response to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, a lung biopsy revealed a transcriptomic profile of the tumor immune microenvironment with a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive clinical response to atezolizumab therapy? Start by assessing the patient's natural killer cell activity using the COMPASS assay. Simultaneously, order laboratory tests to evaluate markers of T-cell exhaustion and to determine the functionality of B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to gauge the level of immune activation. This thorough evaluation is essential for identifying potential immunodeficiencies and for developing a customized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"For a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 11.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), a tumor mutational burden of 11.0, and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by evaluating the patient's natural killer cell function using the COMPASS assay. At the same time, request laboratory tests to assess markers of T-cell exhaustion and to evaluate the performance of both B cells and plasma cells. Once the data are available, calculate the COMPASS score and correlate it with the patient’s transcriptomic profile to determine the extent of immune activation. This comprehensive analysis is crucial for detecting any immunodeficiencies and for designing a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized through transcriptomic profiling and who has a tumor mutational burden of 4.0, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment has been characterized through transcriptomic profiling and who has a tumor mutational burden of 4.0, what is the likelihood that she will respond favorably to Atezolizumab therapy? Start by assessing natural killer cell function using the COMPASS assay. Concurrently, order laboratory tests to evaluate markers of T-cell exhaustion and to assess the function of B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare it with the patient's transcriptomic profile to gauge the level of immune activation. This comprehensive evaluation is essential for identifying potential immunodeficiencies and for tailoring a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma, I have obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is not quantifiable. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma, I have obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy. However, the tumor mutational burden is not quantifiable. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by evaluating natural killer cell function using the COMPASS assay. Simultaneously, order laboratory tests to assess markers of T‐cell exhaustion and to evaluate the function of B cells and plasma cells. Once these results are available, calculate the COMPASS score and correlate this with the patient's transcriptomic profile to determine the degree of immune activation. This comprehensive evaluation is critical for identifying potential immunodeficiencies and for tailoring a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment and has an unknown tumor mutation burden, what is the expected likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, who underwent a bladder biopsy with transcriptomic profiling of the tumor immune microenvironment and has an unknown tumor mutation burden, what is the expected likelihood of a positive response to atezolizumab therapy? First, assess natural killer cell activity using the COMPASS assay. At the same time, request laboratory tests to evaluate T-cell exhaustion markers and to measure B cell and plasma cell functions. Once you have the test results, calculate the COMPASS score and compare it with the patient's transcriptomic profile to determine the level of immune activation. This thorough evaluation is essential for detecting any immunodeficiencies and for developing a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"In a White male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment and determined that the tumor mutational burden is 18.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a White male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment and determined that the tumor mutational burden is 18.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by evaluating natural killer cell function using the COMPASS assay. Concurrently, order laboratory tests to assess markers of T-cell exhaustion as well as measures of B cell and plasma cell activity. When you receive the results, calculate the COMPASS score and cross-reference it with the patient's transcriptomic profile to gauge the extent of immune activation. This comprehensive workup is crucial for identifying potential immunodeficiencies and for guiding the development of a personalized immunotherapy approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"For my white male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 19.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 19.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Start by assessing natural killer cell function with the COMPASS assay. At the same time, request laboratory studies to measure markers for T-cell exhaustion, as well as B-cell and plasma cell activity. When the results are in, compute the COMPASS score and compare it with the patient’s transcriptomic data. This integrated evaluation is essential for identifying potential immunodeficiencies and will help tailor a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"For my Caucasian patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 35.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 35.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Begin by evaluating the activity of natural killer cells using the COMPASS assay. Concurrently, order laboratory tests to quantify markers of T-cell exhaustion and assess B-cell and plasma cell activity. After obtaining the results, calculate the COMPASS score and compare it with the patient's transcriptomic profile. This comprehensive analysis is crucial for pinpointing potential immunodeficiencies and guiding the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Please start by assessing natural killer cell function with the COMPASS assay. At the same time, request laboratory analyses to measure T-cell exhaustion markers and evaluate B-cell and plasma cell activity. Once you have these results, calculate the COMPASS score and compare it to the patient’s transcriptomic profile. This integrated evaluation is essential for identifying any immunodeficiencies and will help guide the formulation of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"For my white male patient with bladder urothelial carcinoma, the tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, how likely is it that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 5.0. Based on these findings, how likely is it that he will respond favorably to Atezolizumab therapy? Begin by evaluating natural killer cell function using the COMPASS assay. Concurrently, order laboratory tests to assess T-cell exhaustion markers and to analyze B-cell and plasma cell activity. Once these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. This integrated assessment is critical for detecting immunodeficiencies and will assist in developing a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma and a tumor mutation burden of 16.0, how likely is a favorable response to Atezolizumab based on the transcriptomic profile of the tumor immune microenvironment obtained from their bladder biopsy?","For my Caucasian patient with bladder urothelial carcinoma and a tumor mutation burden of 16.0, how likely is a favorable response to Atezolizumab based on the transcriptomic profile of the tumor immune microenvironment obtained from their bladder biopsy? Start by assessing natural killer cell function with the COMPASS assay. At the same time, request laboratory tests to measure markers of T-cell exhaustion and to evaluate the activity of B cells and plasma cells. Once you have these results, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This comprehensive approach is essential for identifying immunodeficiencies and will inform the development of a tailored immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"For a patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, how might the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy predict the likelihood of a positive response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma and a tumor mutational burden of 8.0, how might the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy predict the likelihood of a positive response to Atezolizumab therapy? Begin by evaluating natural killer cell function using the COMPASS assay while simultaneously ordering laboratory tests to assess markers of T-cell exhaustion and the activity levels of B cells and plasma cells. Once these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This integrated approach is fundamental for detecting immunodeficiencies and will help guide the development of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For my white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0, and with transcriptomic profiling of the tumor immune microenvironment available, what is the expected likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0, and with transcriptomic profiling of the tumor immune microenvironment available, what is the expected likelihood of a positive response to atezolizumab therapy? Assess natural killer cell function using the COMPASS assay and, at the same time, order laboratory tests to evaluate markers of T-cell exhaustion as well as the activity of B cells and plasma cells. Once these results are available, calculate the COMPASS score and compare it with the patient's transcriptomic profile. This integrated analysis is essential for identifying immunodeficiencies and will help tailor a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For a White female patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment was performed on a kidney biopsy and the tumor shows a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma, where a transcriptomic analysis of the tumor immune microenvironment was performed on a kidney biopsy and the tumor shows a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's natural killer cell function using the COMPASS assay while concurrently ordering laboratory tests to measure markers of T-cell exhaustion and assess the activity levels of B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare it with the patient's transcriptomic profile. This comprehensive analysis is crucial for detecting immunodeficiencies and will inform the development of an individualized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 7.0. Based on these results, what is her likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 7.0. Based on these results, what is her likelihood of a positive response to Atezolizumab therapy? Please assess the patient's natural killer cell function using the COMPASS assay and simultaneously order laboratory tests to evaluate T-cell exhaustion markers and determine the activity levels of B cells and plasma cells. When the results are available, compute the COMPASS score and compare it with the patient's transcriptomic data. This integrative analysis is essential for identifying any immunodeficiencies and will guide the creation of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment has been performed, although the tumor mutation burden data are unavailable. Based on this information, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment has been performed, although the tumor mutation burden data are unavailable. Based on this information, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please evaluate the patient's natural killer cell function using the COMPASS assay. At the same time, order laboratory tests to assess markers of T-cell exhaustion and the activity of B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This comprehensive evaluation will help identify any immunodeficiencies and inform the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"What is the likelihood of a positive response to Atezolizumab in a white male patient with bladder urothelial carcinoma, given a tumor mutation burden of 9.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy?","What is the likelihood of a positive response to Atezolizumab in a white male patient with bladder urothelial carcinoma, given a tumor mutation burden of 9.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy? Please assess the patient's natural killer cell function using the COMPASS assay. Simultaneously, order laboratory tests to evaluate markers of T-cell exhaustion and to assess the activity levels of B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. This thorough evaluation will help identify any underlying immunodeficiencies and guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 20.0, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 20.0, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy? Evaluate the patient's natural killer cell function using the COMPASS assay. At the same time, request laboratory tests to investigate T-cell exhaustion markers, and to assess B cell and plasma cell activity. After receiving the results, calculate the COMPASS score and correlate it with the patient's transcriptomic data. This comprehensive assessment is intended to uncover potential immunodeficiencies and support the design of an individualized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"In a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 10.0, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy was performed. Based on these parameters, how likely is it that the patient will respond favorably to Atezolizumab therapy?","In a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 10.0, transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy was performed. Based on these parameters, how likely is it that the patient will respond favorably to Atezolizumab therapy? Please assess the patient’s natural killer cell function using the COMPASS assay procedure. Concurrently, order laboratory evaluations to examine markers of T-cell exhaustion, as well as tests to determine B cell and plasma cell activity. Once the results are available, calculate the COMPASS score and compare these findings with the patient's transcriptomic data. This comprehensive approach is designed to identify any underlying immunodeficiencies and guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"For a White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 35, based on the transcriptomic analysis of the tumor immune microenvironment from the bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a White patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 35, based on the transcriptomic analysis of the tumor immune microenvironment from the bladder biopsy, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please evaluate the patient's natural killer (NK) cell activity using the COMPASS assay protocol. In addition, order laboratory tests to assess markers indicative of T-cell exhaustion and to examine the activity of B cells and plasma cells. Once the test results are available, compute the COMPASS score and compare these findings with the patient’s transcriptomic data. This integrated assessment is intended to uncover any underlying immunodeficiencies and assist in formulating a tailored immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"In a white female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden (TMB) of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's natural killer (NK) cell activity using the COMPASS assay protocol. Additionally, please order laboratory tests to measure markers of T-cell exhaustion and assess the functional activity of B cells and plasma cells. Once the results are available, calculate the COMPASS score and compare these findings with the patient's transcriptomic data. This comprehensive evaluation aims to identify any underlying immunodeficiencies and guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 3.0. Based on this data, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a TMB of 3.0. Based on this data, what is the likelihood of a positive response to Atezolizumab therapy? Please assess the patient's natural killer cell function according to the COMPASS assay protocol. In addition, order laboratory tests to evaluate markers of T-cell exhaustion as well as the functional status of both B cells and plasma cells. Once the results are obtained, calculate the COMPASS score and compare these findings with the patient’s transcriptomic data. This comprehensive approach is expected to help identify any underlying immunodeficiency and inform the formulation of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma, the tumor mutational burden is 5.0, and transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy. Given these factors, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, the tumor mutational burden is 5.0, and transcriptomic profiling of the tumor immune microenvironment has been performed on a bladder biopsy. Given these factors, what is the estimated likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's natural killer (NK) cell activity using the COMPASS assay protocol. Additionally, order laboratory tests to assess markers of T-cell exhaustion and to determine the functional status of both B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This detailed evaluation will aid in identifying any underlying immunodeficiencies and support the development of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via nanobiopsy and has a TMB of 5.0, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via nanobiopsy and has a TMB of 5.0, what is the likelihood of achieving a positive response to Atezolizumab therapy? Please assess the patient's natural killer (NK) cell function using the COMPASS assay protocol. In addition, request laboratory tests to measure markers indicating T-cell exhaustion and to evaluate the functionality of both B cells and plasma cells. Once the test results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This comprehensive evaluation will help identify any underlying immunodeficiencies and inform the development of an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 5.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic analysis from a bladder biopsy indicates a tumor mutational burden of 5.0, what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's natural killer (NK) cell activity using the COMPASS assay protocol. Additionally, order laboratory tests to assess markers of T-cell exhaustion and to measure the function of both B cells and plasma cells. Once you receive the test results, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This detailed evaluation will help identify any underlying immunodeficiencies and support the development of a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA), where a transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and the tumor mutational burden is 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), where a transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and the tumor mutational burden is 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please assess the patient’s NK cell activity using the COMPASS assay protocol. In addition, order the necessary laboratory tests to evaluate T-cell exhaustion markers and to assess the functional status of both B cells and plasma cells. Once the results are available, calculate the patient’s COMPASS score and compare it with their transcriptomic data. This thorough evaluation is essential for identifying any potential immunodeficiencies and will aid in formulating a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutation burden (TMB) is not available, based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutation burden (TMB) is not available, based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's NK cell activity using the COMPASS assay protocol. Additionally, order laboratory tests to measure T-cell exhaustion markers and assess the function of B cells and plasma cells. Once you receive the results, calculate the COMPASS score and compare it with the patient's transcriptomic data. This thorough assessment is crucial for identifying potential immunodeficiencies and will help guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"For a patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden (TMB) of 3.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden (TMB) of 3.0 and a characterized transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Please assess the patient's natural killer (NK) cell function using the COMPASS assay. In addition, order laboratory tests to evaluate T-cell exhaustion, as well as the function of B cells and plasma cells. Once the results are obtained, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. This comprehensive evaluation is essential for identifying potential immunodeficiencies and will inform the design of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 10.0, what is the likelihood of a positive therapeutic response to Atezolizumab?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose ureter biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden (TMB) of 10.0, what is the likelihood of a positive therapeutic response to Atezolizumab? Please perform an analysis of the patient's natural killer (NK) cell function using the COMPASS assay. In addition, order laboratory evaluations to assess T-cell exhaustion and to determine the functional status of B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. This thorough evaluation is critical for identifying potential immunodeficiencies and will guide the development of a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"For a white male patient with bladder urothelial carcinoma, based on transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 3.0, how likely is a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, based on transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy and a tumor mutational burden of 3.0, how likely is a favorable response to atezolizumab therapy? Please evaluate the patient's natural killer (NK) cell function using the COMPASS assay. Additionally, order laboratory tests to assess T-cell exhaustion and evaluate the functional status of both B cells and plasma cells. Once these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. This comprehensive evaluation is necessary to identify any immunodeficiencies and will help guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a TMB of 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a TMB of 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please assess the patient's natural killer cell activity by performing the COMPASS assay. In addition, please order laboratory tests to evaluate T-cell exhaustion and assess the functional status of both B cells and plasma cells. Once the test results are obtained, calculate the COMPASS score and compare it to the patient's transcriptomic profile. This detailed evaluation is essential for identifying potential immunodeficiencies and will inform the development of a tailored immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"For my Black or African American female patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and noted a tumor mutation burden (TMB) of 11.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Black or African American female patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy and noted a tumor mutation burden (TMB) of 11.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Evaluate the patient's natural killer cell activity using the COMPASS assay. Additionally, order laboratory tests to assess T-cell exhaustion and the functional status of B cells and plasma cells. After obtaining these results, calculate the COMPASS score and correlate it with the patient’s transcriptomic data. This comprehensive analysis is vital for detecting potential immunodeficiencies and will help guide a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden data is unavailable. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, but the tumor mutational burden data is unavailable. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Assess the patient's natural killer cell activity using the COMPASS assay. Additionally, request laboratory evaluations to determine levels of T-cell exhaustion and to measure the functionality of both B cells and plasma cells. Once you receive the results, compute the COMPASS score and compare it with the patient's transcriptomic data. This comprehensive analysis is essential for identifying potential immunodeficiencies and will inform the development of a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who underwent transcriptomic profiling of the tumor immune microenvironment from a liver biopsy and has an unavailable tumor mutation burden, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who underwent transcriptomic profiling of the tumor immune microenvironment from a liver biopsy and has an unavailable tumor mutation burden, what is the estimated likelihood of a positive response to atezolizumab therapy? Please evaluate the patient’s natural killer cell activity using the COMPASS assay. Additionally, order laboratory tests to assess markers of T-cell exhaustion and to evaluate the function of both B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This comprehensive analysis will help identify any potential immunodeficiencies and guide the formulation of an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"For a white female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 26.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 26.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Evaluate the patient’s natural killer cell function using the COMPASS assay. In addition, request laboratory tests to assess markers indicative of T-cell exhaustion and to determine the functional status of B cells and plasma cells. Once the test results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data. This comprehensive evaluation will help identify any potential immunodeficiencies and assist in developing a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0, having obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma and a tumor mutational burden of 14.0, having obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Assess the patient's natural killer cell activity using the COMPASS assay. Additionally, order laboratory tests to evaluate markers related to T-cell exhaustion and to assess the functionality of B cells and plasma cells. Once you have the results, calculate the COMPASS score and compare it with the patient's transcriptomic profile. This comprehensive approach will help identify any immunodeficiencies and inform a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For my Caucasian patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy, while the tumor mutation burden is currently undetermined. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy, while the tumor mutation burden is currently undetermined. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Evaluate the patient's natural killer cell function using the COMPASS assay. In addition, request laboratory testing to measure markers of T-cell exhaustion and to assess the performance of B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient's transcriptomic profile. This comprehensive evaluation will help determine any immunodeficiencies and guide a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and the tumor mutation burden is 4.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and the tumor mutation burden is 4.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy? Assess the patient's immune function by measuring natural killer cell activity with the COMPASS assay. Additionally, order laboratory tests to evaluate T‐cell exhaustion markers along with assessments of B-cell and plasma cell function. Once you have the results, calculate the COMPASS score and compare it with the patient's transcriptomic profile to identify any immunodeficiencies and guide the development of a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive clinical response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden (TMB) of 3.0. Based on these findings, what is the anticipated likelihood of a positive clinical response to atezolizumab therapy? Evaluate the patient's immune status by first measuring natural killer cell activity using the COMPASS assay. In addition, request laboratory tests to assess markers of T-cell exhaustion and to evaluate both B-cell and plasma cell functions. After obtaining these results, calculate the COMPASS score and compare it against the patient's transcriptomic profile to detect potential immunodeficiencies and to inform a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis reveals the tumor immune microenvironment characteristics and a tumor mutational burden of 22, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis reveals the tumor immune microenvironment characteristics and a tumor mutational burden of 22, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy? Assess the patient's immune function by initially measuring natural killer cell activity via the COMPASS assay. Additionally, order laboratory evaluations to examine indicators of T-cell exhaustion and assess the functions of both B cells and plasma cells. Once these data are available, compute the COMPASS score and correlate it with the patient’s transcriptomic profile to identify any immunodeficiencies and help guide a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, how likely is it that the patient will respond favorably to Atezolizumab therapy? Begin by evaluating the patient’s immune function. First, measure natural killer cell activity using the COMPASS assay. Next, order laboratory tests to assess markers of T-cell exhaustion as well as the functionality of B cells and plasma cells. Once you have these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. Use this integrated information to identify any immunodeficiencies and inform a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a white female patient with bladder urothelial carcinoma, where a transcriptomic profile of the tumor immune microenvironment was obtained from a lymph node biopsy and the tumor mutational burden is 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, where a transcriptomic profile of the tumor immune microenvironment was obtained from a lymph node biopsy and the tumor mutational burden is 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by assessing the patient’s immune status. First, use the COMPASS assay to quantify natural killer cell activity. Next, request laboratory tests to evaluate markers of T-cell exhaustion and to assess the functionality of B and plasma cells. Once you have obtained these data, calculate the COMPASS score and compare it with the patient’s transcriptomic profile. Integrate these findings to detect any immunodeficiencies and to guide a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a kidney biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 62.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a kidney biopsy–derived transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 62.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Start by evaluating the patient's immune function. First, perform a COMPASS assay to measure natural killer cell activity. Concurrently, order laboratory tests to assess markers of T-cell exhaustion and to evaluate the function of B cells and plasma cells. Once you have these results, calculate the COMPASS score and compare it with the patient's transcriptomic profile. Use this integrated information to identify any immunodeficiencies and to develop a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and whose tumor immune microenvironment was evaluated via transcriptomic profiling from a recent biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and whose tumor immune microenvironment was evaluated via transcriptomic profiling from a recent biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Begin by assessing the patient's overall immune function. Begin with a COMPASS assay to evaluate natural killer cell activity while simultaneously ordering additional laboratory tests that assess T-cell exhaustion markers and examine B-cell and plasma cell functionality. Once you have gathered these results, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to identify any immunodeficiencies. Use this comprehensive data to formulate a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"For our Caucasian patient with bladder urothelial carcinoma, whose tumor immune microenvironment profiling from a lymph node biopsy has revealed a TMB of 7.0, what is the likelihood of a favorable response to atezolizumab therapy?","For our Caucasian patient with bladder urothelial carcinoma, whose tumor immune microenvironment profiling from a lymph node biopsy has revealed a TMB of 7.0, what is the likelihood of a favorable response to atezolizumab therapy? Start by evaluating the patient’s immune system. First, perform a COMPASS assay to assess natural killer cell activity, and concurrently order lab tests to measure T-cell exhaustion markers and evaluate B-cell and plasma cell functions. Once all results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to determine the presence of any immunodeficiencies. Use this comprehensive data to develop a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"For my patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy and a tumor mutation burden of 15.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy and a tumor mutation burden of 15.0, what is the likelihood of a positive response to Atezolizumab therapy? Commence by thoroughly assessing the patient’s immune status. Begin with a COMPASS assay to evaluate natural killer cell activity, while simultaneously ordering laboratory tests to measure markers of T-cell exhaustion and to assess B-cell and plasma cell function. Once you have all the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to detect any underlying immunodeficiencies. Use this integrated data to develop a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and whose tumor immune microenvironment was characterized by transcriptomic profiling from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 5.0 and whose tumor immune microenvironment was characterized by transcriptomic profiling from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy? Begin by conducting a comprehensive evaluation of the patient’s immune status. Start with a COMPASS assay to assess natural killer cell activity, and at the same time, order laboratory tests to measure markers of T-cell exhaustion as well as to evaluate B-cell and plasma cell function. Once you have received all the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to identify any underlying immunodeficiencies. Use these integrated findings to develop a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The patient's tumor mutational burden (TMB) data is not available. Based on these results, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The patient's tumor mutational burden (TMB) data is not available. Based on these results, what is the likelihood of a positive response to atezolizumab therapy? Start by thoroughly assessing the patient’s immune status. Order a COMPASS assay to evaluate natural killer cell function and simultaneously request laboratory tests to measure T-cell exhaustion markers and assess B-cell and plasma cell function. Once you have all the results, compute the COMPASS score and compare it with the patient’s transcriptomic data to identify any underlying immunodeficiencies. Finally, use this integrated information to tailor a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment was performed from a ureter biopsy, and the reported tumor mutational burden (TMB) is ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment was performed from a ureter biopsy, and the reported tumor mutational burden (TMB) is ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by conducting a comprehensive evaluation of the patient’s immune status. Request a COMPASS assay to determine natural killer cell function and simultaneously order laboratory tests to assess T-cell exhaustion markers as well as B-cell and plasma cell function. Once you receive all test results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to detect potential immunodeficiencies. Finally, use this combined information to develop a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"For my white male patient with bladder urothelial carcinoma, a recent transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 24. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a recent transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 24. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? First, perform a comprehensive assessment of the patient’s immune function. Order a COMPASS assay to evaluate natural killer cell activity and request additional laboratory tests to measure markers of T-cell exhaustion as well as the function of B-cells and plasma cells. Once you have all the results, calculate the COMPASS score and compare it with the patient's transcriptomic profile to identify any potential immunodeficiencies. Use this integrated data to design a personalized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. The analysis indicates a tumor mutation burden (TMB) reported as ""nan."" Based on these factors, how likely is the patient to respond positively to atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. The analysis indicates a tumor mutation burden (TMB) reported as ""nan."" Based on these factors, how likely is the patient to respond positively to atezolizumab therapy? Begin by conducting a comprehensive evaluation of the patient’s immune function. Initiate testing with a COMPASS assay to measure natural killer cell activity, and include additional laboratory studies to assess markers of T-cell exhaustion along with the function of B-cells and plasma cells. Once all laboratory results are available, determine the COMPASS score and compare it with the patient’s transcriptomic profile to identify any underlying immunodeficiencies. Use this integrated information to formulate a tailored immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment via a ureteral biopsy. With a tumor mutational burden of 8.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained transcriptomic profiling of the tumor immune microenvironment via a ureteral biopsy. With a tumor mutational burden of 8.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin by performing a thorough assessment of the patient's immune system. Start with a COMPASS assay to evaluate natural killer cell activity, and include additional tests to assess markers of T-cell exhaustion and the function of B-cells and plasma cells. Once the laboratory results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to detect any immunodeficiencies. Use this comprehensive data to develop an individualized immunotherapy strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"For my white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden (TMB) of 4.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Start with a comprehensive evaluation of the patient's immune system. First, perform a COMPASS assay to assess the activity of natural killer cells, and supplement this with tests that measure markers of T-cell exhaustion and evaluate the function of B-cells and plasma cells. After obtaining the lab results, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to identify any immunodeficiencies. Use the combined information to design a customized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutation burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutation burden of 14.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by thoroughly evaluating the patient’s immune system. Begin with a COMPASS assay to assess natural killer cell activity, and complement this test with assessments for T-cell exhaustion markers as well as evaluations of B-cell and plasma cell function. Once all laboratory results are available, determine the COMPASS score and compare it with the patient's transcriptomic profile to identify any immunodeficiencies. Use this integrated information to develop a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 5.0. Based on these parameters, how likely is he to respond positively to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 5.0. Based on these parameters, how likely is he to respond positively to Atezolizumab therapy? Start by performing a comprehensive evaluation of the patient’s immune status. Initially, conduct a COMPASS assay to measure natural killer cell activity. In addition, assess markers of T-cell exhaustion and evaluate the functional status of B-cells and plasma cells. Once you have obtained all the laboratory data, calculate the COMPASS score and analyze it alongside the patient’s transcriptomic profile to detect any immunodeficiencies. Use this integrated analysis to formulate a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 10.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is 10.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Begin with a thorough evaluation of the patient's immune system. Start by performing a COMPASS assay to assess natural killer cell activity. Also, measure markers of T-cell exhaustion and evaluate the function of both B-cells and plasma cells. After gathering all laboratory data, calculate the COMPASS score and review it together with the patient’s transcriptomic profile to identify any immunodeficiencies. Use this comprehensive analysis to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden (TMB) is not quantifiable. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden (TMB) is not quantifiable. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy? Begin by thoroughly evaluating the patient’s immune function. First, perform a COMPASS assay to measure natural killer cell activity, assess markers indicative of T-cell exhaustion, and evaluate the functional status of both B-cells and plasma cells. Once you have collected all the relevant laboratory data, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to detect any signs of immunodeficiency. Use the outcomes of this detailed analysis to develop an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy shows an indeterminate tumor mutational burden, what is the likelihood that he will respond favorably to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy shows an indeterminate tumor mutational burden, what is the likelihood that he will respond favorably to atezolizumab therapy? Start by conducting a comprehensive assessment of the patient's immune function. Perform a COMPASS assay to evaluate natural killer cell activity, assess markers for T-cell exhaustion, and determine the functional status of both B-cells and plasma cells. Once you have obtained the laboratory data, calculate the COMPASS score and compare it with the patient's transcriptomic profile to identify any indications of immunodeficiency. Use these findings to design a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Begin by carrying out a detailed evaluation of the patient’s immune system. This includes performing a COMPASS assay to measure natural killer cell activity, assessing markers of T-cell exhaustion, and evaluating the functionality of both B-cells and plasma cells. After obtaining the lab results, calculate the COMPASS score and correlate it with the patient’s transcriptomic profile to determine the presence of any immunodeficiency. Use this comprehensive information to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For my patient with bladder urothelial carcinoma, whose ureter biopsy provided transcriptomic profiling of the tumor immune microenvironment and who has a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to atezolizumab therapy?","For my patient with bladder urothelial carcinoma, whose ureter biopsy provided transcriptomic profiling of the tumor immune microenvironment and who has a tumor mutational burden of 5.0, what is the expected likelihood of a positive response to atezolizumab therapy? First, conduct a comprehensive assessment of the patient’s immune system. This should include a COMPASS assay to evaluate natural killer cell activity, tests for markers of T-cell exhaustion, and functional analyses of both B-cells and plasma cells. Once you receive the laboratory results, calculate the COMPASS score and compare it with the patient's transcriptomic profile to assess for any immunodeficiency. Use these findings to formulate a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden of 2.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden of 2.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Begin by performing a detailed evaluation of the patient’s immune function. This evaluation should include a COMPASS assay to measure natural killer cell activity, along with tests to detect markers indicating T-cell exhaustion and functional assessments of both B-cells and plasma cells. After obtaining the laboratory results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to determine the presence of any immunodeficiency. Finally, use this integrated information to develop a tailored immunotherapy treatment plan for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and whose bladder biopsy transcriptomic analysis characterizes the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and whose bladder biopsy transcriptomic analysis characterizes the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy? Start by thoroughly evaluating the patient’s immune function. This should include a COMPASS assay to assess natural killer cell activity, tests for markers of T-cell exhaustion, and functional evaluations of both B-cells and plasma cells. Once the lab results are available, calculate the COMPASS score and correlate it with the patient’s transcriptomic data to identify any signs of immunodeficiency. Use this comprehensive information to develop a customized immunotherapy treatment plan for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"For my White female patient diagnosed with bladder urothelial carcinoma, whose nano-biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 17.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my White female patient diagnosed with bladder urothelial carcinoma, whose nano-biopsy transcriptomic profiling of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 17.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin by conducting a comprehensive assessment of the patient’s immune function. This evaluation should include a COMPASS assay to measure natural killer cell activity, analyses for T-cell exhaustion markers, and functional assessments of both B-cells and plasma cells. Once you have obtained the laboratory results, calculate the COMPASS score and compare it with the patient's transcriptomic data to identify any potential immunodeficiency. Use these integrated findings to design a personalized immunotherapy treatment plan for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutation burden (TMB) data is not available. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutation burden (TMB) data is not available. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy? Start by performing a thorough evaluation of the patient's immune function. This should include a COMPASS assay to determine natural killer cell activity, measurements of T-cell exhaustion markers, and functional tests for both B-cells and plasma cells. Once you have the laboratory results, calculate the COMPASS score and correlate these findings with the patient’s transcriptomic data to identify any signs of immunodeficiency. Use this integrated information to develop a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0 mutations per megabase. Based on these findings, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 6.0 mutations per megabase. Based on these findings, what is the expected likelihood of a favorable response to atezolizumab therapy? Begin with a comprehensive assessment of the patient’s immune system. This evaluation should include a COMPASS assay to measure natural killer cell activity, tests for T-cell exhaustion markers, and functional assessments of B-cells and plasma cells. After obtaining the laboratory results, calculate the COMPASS score and compare these findings with the patient’s transcriptomic data to detect any potential immunodeficiency. Use this combined information to design a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 9.0, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 9.0, what is the estimated likelihood of a favorable response to atezolizumab therapy? Start by thoroughly evaluating the patient's immune function. Perform a COMPASS assay to assess natural killer cell activity, along with tests for T-cell exhaustion markers and functional evaluations of B-cells and plasma cells. Once you have the laboratory data, calculate the COMPASS score and integrate these results with the patient’s transcriptomic profile to identify any signs of immunodeficiency. Use the combined findings to develop a customized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For a white female patient with confirmed bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of achieving a positive response to Atezolizumab therapy?","For a white female patient with confirmed bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of achieving a positive response to Atezolizumab therapy? Begin by conducting a comprehensive immune evaluation. This should include a COMPASS assay to assess natural killer cell activity, as well as tests for markers of T-cell exhaustion and functional assays for B-cells and plasma cells. After obtaining these laboratory results, calculate the COMPASS score and analyze it in conjunction with the patient’s transcriptomic profile to detect any indications of immunodeficiency. Finally, use the combined data to develop a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has a TMB of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has a TMB of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Start with a detailed immune evaluation. This should include a COMPASS assay to assess natural killer cell function, tests for markers of T-cell exhaustion, and functional assays for both B-cells and plasma cells. Once you have the results, calculate the COMPASS score and integrate these findings with the patient’s transcriptomic profile to identify any signs of immunodeficiency. Use this comprehensive analysis to design a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy; however, his tumor mutation burden is unavailable. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic data of the tumor immune microenvironment from a bladder biopsy; however, his tumor mutation burden is unavailable. Based on these parameters, what is the likelihood of a positive response to atezolizumab therapy? Begin with an extensive immune evaluation, which should include a COMPASS assay to measure natural killer cell functionality, assessments for T-cell exhaustion markers, and functional analyses for B-cells and plasma cells. Once the data are collected, calculate the COMPASS score and correlate these results with the patient’s transcriptomic profile to detect any indications of immunodeficiency. Use this integrated information to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is reported as not a number. Given these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is reported as not a number. Given these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Begin with a comprehensive immune assessment that includes a COMPASS assay to evaluate natural killer cell activity, along with tests for T-cell exhaustion and functional evaluations of B-cells and plasma cells. Once you obtain these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any evidence of immunodeficiency. Use the combined data to design a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden is 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden is 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Begin with a full immune evaluation that includes performing the COMPASS assay to assess natural killer cell activity, along with tests to determine T-cell exhaustion and to evaluate the function of B-cells and plasma cells. Once these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any signs of immunodeficiency. Use this combined information to formulate a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), where the tumor immune microenvironment transcriptomic profile has been characterized and the tumor mutation burden is 1.0, what is the likelihood of a positive therapeutic response to atezolizumab?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), where the tumor immune microenvironment transcriptomic profile has been characterized and the tumor mutation burden is 1.0, what is the likelihood of a positive therapeutic response to atezolizumab? Start by conducting a comprehensive immune assessment. This should include the COMPASS assay to evaluate natural killer cell function, tests for T-cell exhaustion, and evaluations of B-cell and plasma cell activity. Once you have these results, calculate the COMPASS score and compare it to the patient’s transcriptomic profile to assess for any signs of immunodeficiency. Use the combined findings from these evaluations to develop an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"In a white male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment has been performed and tumor mutation burden (TMB) data is unavailable, how should these findings inform the expected response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment has been performed and tumor mutation burden (TMB) data is unavailable, how should these findings inform the expected response to Atezolizumab therapy? Begin by performing a comprehensive immune evaluation. This evaluation should include using the COMPASS assay to assess natural killer cell function, conducting tests for T-cell exhaustion, and evaluating both B-cell and plasma cell activity. After obtaining these results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify potential immunodeficiencies. Finally, integrate these findings to formulate a personalized immunotherapy treatment plan for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, how likely is the patient to achieve a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 6.0. Based on these findings, how likely is the patient to achieve a positive response to Atezolizumab therapy? Start with a full immune workup that includes a COMPASS assay for assessing natural killer cell function, tests to determine T-cell exhaustion, and evaluations of both B-cell and plasma cell activities. Once you have these results, compute the COMPASS score and correlate it with the patient's transcriptomic data to identify any immunodeficiencies. Use all of these findings to develop a tailored immunotherapy treatment plan for the patient.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy indicates a tumor immune microenvironment profile, and her tumor mutation burden is 3.0. Based on these findings, what is the likelihood that she will respond positively to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, a transcriptomic analysis from a bladder biopsy indicates a tumor immune microenvironment profile, and her tumor mutation burden is 3.0. Based on these findings, what is the likelihood that she will respond positively to atezolizumab therapy? Please obtain a comprehensive immune panel that encompasses a COMPASS assay to assess natural killer cell function, specific tests for T-cell exhaustion, and evaluations of both B-cell and plasma cell activities. Once these results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any immunodeficiencies. Finally, integrate all this data to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"For my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 7.0, what is the likelihood of a positive therapeutic response to Atezolizumab based on the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy?","For my white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 7.0, what is the likelihood of a positive therapeutic response to Atezolizumab based on the transcriptomic profile of his tumor immune microenvironment obtained from a bladder biopsy? Please initiate a comprehensive immune panel that includes a COMPASS assay to evaluate natural killer cell function, as well as targeted tests to assess T-cell exhaustion and the activities of B cells and plasma cells. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify potential immunodeficiencies. Use this integrated information to formulate a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 14.0 and transcriptomic data from the tumor immune microenvironment obtained via bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Begin by ordering a comprehensive immune panel that includes a COMPASS assay for assessing natural killer cell function, along with specific tests to evaluate T-cell exhaustion and the function of B cells and plasma cells. Once you obtain the results, compute the COMPASS score and correlate it with the patient’s transcriptomic data to identify any underlying immunodeficiencies. Use this integrated analysis to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For my white male patient with a diagnosis of bladder urothelial carcinoma, who has a tumor mutational burden of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained from biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with a diagnosis of bladder urothelial carcinoma, who has a tumor mutational burden of 2.0 and a transcriptomic profile of the tumor immune microenvironment obtained from biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Request a comprehensive immune panel that includes a COMPASS assay to evaluate natural killer cell activity, as well as targeted assessments for T-cell exhaustion and both B cell and plasma cell function. Once the results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data to detect any potential immunodeficiencies. Use this combined analysis to formulate a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, which shows a tumor mutational burden (TMB) value of ""nan."" Based on these findings, what can we infer about his potential response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, which shows a tumor mutational burden (TMB) value of ""nan."" Based on these findings, what can we infer about his potential response to atezolizumab therapy? Please order a detailed immune panel that includes a COMPASS assay to assess natural killer cell activity. Additionally, include tests specifically targeting markers of T-cell exhaustion as well as assessments of B-cell and plasma cell function. After obtaining the results, calculate the COMPASS score and compare it with the patient’s transcriptomic data to identify any underlying immunodeficiencies. Use these integrated findings to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and for whom tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and for whom tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please order a comprehensive immune evaluation that includes a COMPASS assay to assess natural killer cell function. Also, include tests that specifically evaluate markers of T-cell exhaustion as well as B-cell and plasma cell activity. Once the results are obtained, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to detect any underlying immunodeficiency. Use this combined information to formulate an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For a White male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was obtained from a lung biopsy and the tumor mutation burden is 1.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was obtained from a lung biopsy and the tumor mutation burden is 1.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please request a full immune workup that comprises a COMPASS assay to assess natural killer cell function. Additionally, order tests focused on markers indicative of T-cell exhaustion and evaluations of B-cell and plasma cell activity. Once the results are available, please compute the COMPASS score and cross-reference it with the patient’s transcriptomic data to identify any potential immunodeficiencies. Use this integrated information to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"For our Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For our Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please obtain a comprehensive immune profile for the patient, including a COMPASS assay to evaluate natural killer cell function. Additionally, order assessments for T-cell exhaustion markers, as well as evaluations of B-cell and plasma cell activity. When the results are available, calculate the COMPASS score and compare it with the patient’s transcriptomic data to detect any immunodeficiencies. Use this integrated information to develop a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 14.0 and for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 14.0 and for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy, what is the likelihood of a favorable response to atezolizumab therapy? Please obtain a complete immune profile for this patient. This evaluation should include a COMPASS assay to assess natural killer cell function, as well as tests for T-cell exhaustion markers and assessments of both B-cell and plasma cell activity. Once the results are available, calculate the COMPASS score and correlate these findings with the patient’s transcriptomic data to identify any immunodeficiencies. Use this comprehensive information to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"For my African American patient diagnosed with bladder urothelial carcinoma, I evaluated the tumor immune microenvironment using transcriptomic profiling from a bladder biopsy, and the tumor mutational burden is 9.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my African American patient diagnosed with bladder urothelial carcinoma, I evaluated the tumor immune microenvironment using transcriptomic profiling from a bladder biopsy, and the tumor mutational burden is 9.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please perform a comprehensive immunological evaluation of the patient. This should include a COMPASS assay to evaluate natural killer cell function, tests for T-cell exhaustion markers, and assessments of both B-cell and plasma cell activity. After obtaining the results, calculate the COMPASS score and integrate these findings with the patient’s transcriptomic data to identify any immunodeficiencies. Use the gathered data to develop an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 8.0, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 8.0, what is the expected likelihood of a favorable response to atezolizumab therapy? Please conduct a detailed immunological workup for the patient. This should involve a COMPASS assay for natural killer (NK) cell function, assays for T-cell exhaustion markers, and evaluations of B-cell and plasma cell responses. Once you have the results, compute the COMPASS score and correlate these findings with the patient's transcriptomic data to determine any underlying immunodeficiencies. Use this comprehensive assessment to guide the development of a personalized immunotherapy regimen.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden of 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and determined a tumor mutational burden of 7.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please perform a thorough immunological evaluation of the patient. This evaluation should include a COMPASS assay to assess natural killer (NK) cell function, tests to detect markers of T-cell exhaustion, and analyses of B-cell and plasma cell activity. After obtaining the results, calculate the COMPASS score and cross-reference these data with the patient's transcriptomic profile to identify any possible immunodeficiencies. These findings should then be used to formulate a tailored immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"For my Asian female patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling from a kidney biopsy that revealed a tumor mutational burden of 4.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Asian female patient diagnosed with bladder urothelial carcinoma, I obtained transcriptomic profiling from a kidney biopsy that revealed a tumor mutational burden of 4.0. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please conduct a comprehensive immune assessment of the patient. Begin by performing a COMPASS assay to evaluate natural killer cell function, along with tests to identify markers of T-cell exhaustion and assessments of B-cell and plasma cell activity. After gathering these data, calculate the COMPASS score and cross-reference it with the patient’s transcriptomic profile to determine the presence of any immunodeficiencies. Use these results to design a personalized immunotherapy plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutation burden (TMB) of 7.0 mutations/Mb. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutation burden (TMB) of 7.0 mutations/Mb. Given these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please perform a thorough evaluation of the patient’s immune system. Start by administering a COMPASS assay to assess natural killer cell function, and include tests to detect markers of T-cell exhaustion as well as measures of B-cell and plasma cell activity. Once you have collected the data, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any immunodeficiencies. Finally, use these findings to develop an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. However, the tumor mutational burden is reported as ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. However, the tumor mutational burden is reported as ""nan."" Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please conduct a comprehensive assessment of the patient's immune function. Begin by administering the COMPASS assay to evaluate natural killer cell activity, and include additional tests to measure markers of T-cell exhaustion as well as the activity of B-cells and plasma cells. After gathering the data, calculate the COMPASS score and compare it with the patient’s transcriptomic profile in order to identify any potential immunodeficiencies. Use these findings to formulate an individualized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 5.0, what is the estimated probability of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 5.0, what is the estimated probability of a favorable response to Atezolizumab therapy? Please perform a detailed evaluation of the patient's immune function. Start by using the COMPASS assay to assess natural killer cell activity and include additional tests to evaluate markers of T-cell exhaustion, as well as B-cell and plasma cell activity. After collecting the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any potential immunodeficiencies. Use these findings to develop a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, along with a tumor mutation burden of 7.0. Considering these parameters, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, along with a tumor mutation burden of 7.0. Considering these parameters, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please conduct a comprehensive evaluation of the patient's immune system. Begin by administering the COMPASS assay to measure natural killer cell activity. In addition, run tests to assess markers of T-cell exhaustion and to evaluate B-cell and plasma cell functions. Once you have the results, calculate the COMPASS score and compare it with the patient’s transcriptomic profile to identify any immunodeficiency. Use these insights to formulate a personalized immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"In a Caucasian patient with bladder urothelial carcinoma, whose tumor exhibits a tumor mutational burden of 10.0 and transcriptomic profiling of the tumor immune microenvironment from a prior biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma, whose tumor exhibits a tumor mutational burden of 10.0 and transcriptomic profiling of the tumor immune microenvironment from a prior biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please perform a comprehensive immunological assessment. Begin by administering the COMPASS assay to evaluate natural killer cell activity. Additionally, assess T-cell exhaustion markers alongside tests for B-cell and plasma cell function. Once the data is obtained, calculate the COMPASS score and correlate it with the patient's transcriptomic profile to determine the presence of any immunodeficiency. Use these findings to develop a tailored immunotherapy treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
